{
  "name" : "twin.sci-hub.se_7107_37c8021085a74bc60e6f1867d3efd033_gao2017.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for In ammatory Diseases: A Journey from Molecular to Nano Therapeutics",
    "authors" : [ "Wei Gao", "Qiang Li" ],
    "emails" : [ "liqressh@hotmail.com", "hongyang36@gmail.com" ],
    "sections" : [ {
      "heading" : null,
      "text" : "REVIEW published: 19 July 2017\ndoi: 10.3389/fphys.2017.00508\nFrontiers in Physiology | www.frontiersin.org 1 July 2017 | Volume 8 | Article 508\nEdited by: Enrique Hernandez-Lemus, National Institute of Genomic Medicine, Mexico\nReviewed by: Olalekan Michael Ogundele,\nLouisiana State University, United States\nYasser Mohamed El-Wazir, Suez Canal University, Egypt\n*Correspondence: Qiang Li\nliqressh@hotmail.com Hong Yang hongyang36@gmail.com\nSpecialty section: This article was submitted to\nIntegrative Physiology, a section of the journal Frontiers in Physiology\nReceived: 23 April 2017 Accepted: 03 July 2017 Published: 19 July 2017\nCitation: Gao W, Xiong Y, Li Q and Yang H (2017) Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for\nIn ammatory Diseases: A Journey from Molecular to Nano Therapeutics.\nFront. Physiol. 8:508. doi: 10.3389/fphys.2017.00508\nInhibition of Toll-Like Receptor Signaling as a Promising Therapy for In ammatory Diseases: A Journey from Molecular to Nano Therapeutics Wei Gao 1, Ye Xiong 2, Qiang Li 1* and Hong Yang 1*\n1 Department of Respiratory Medicine, Shanghai First People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China,2 Department of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China\nThe recognition of invading pathogens and endogenous molecules from damaged tissues by toll-like receptors (TLRs) triggers protectiveself-defense mechanisms. However, excessive TLR activation disrupts the immune homeostasis by sustained pro-in ammatory cytokines and chemokines production and consequently contributes to the development of many in ammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE), infection-associated sepsis,atherosclerosis, and asthma. Therefore, inhibitors/antagonists targeting TLR signalsmay be bene cial to treat these disorders. In this article, we rst brie y summarize the pathophysiological role of TLRs in the in ammatory diseases. We then focus on reviewing the current knowledge in both preclinical and clinical studies of various TLR antagonists/inhibitors for the prevention and treatment of in ammatory diseases. These compounds range from conventional small molecules to therapeutic biologics and nanodevices.In particular, nanodevices are emerging as a new class of potent TLR inhibitors for theirunique properties in desired bio-distribution, sustained circulation, and preferred pharmacodynamic and pharmacokinetic pro les. More interestingly, the inhibitory activity of these nanodevices can be regulated through precise nano-functionalization,making them the next generation therapeutics or nano-drugs. Although, signi cant efforts have been made in developing different kinds of new TLR inhibitors/antagonists, only limited numbers of them have undergone clinical trials, and none have been approved for clinical uses to date. Nevertheless, these ndings and continuous studies of TLR inhibition highlight the pharmacological regulation of TLR signaling, especially on multiple TLR pathways, as future promising therapeutic strategy for various in ammatory and autoimmune diseases.\nKeywords: toll-like receptor (TLR), autoimmune diseases, in ammatory diseases, in ammation, TLR antagonist, TLR inhibitor, nanotherapeutics\nINTRODUCTION\nToll-like receptors (TLRs) are a family of pattern recognitionreceptors (PRRs) that can recognize and respond to a unique repertoire of distinct molecules referr d to as pathogen-associated molecular patterns (PAMPs) and danger-associated molecularpatterns (DAMPs;Kawai and Akira, 2010; Moresco et al., 2011). These conserved receptors belong to type I transmembrane\nglycoproteins and are made of three structurally important components: (1) the leucine-rich repeat motifs for ligand recognition at N-terminus; (2) a single transmembrane helix; and (3) a conserved cytoplasmic Toll/Interleukin-1 (IL-1) receptor (TIR) domain at C-terminus for intracellular signaling transduction (Botos et al., 2011; Bryant et al., 2015). A representative TLR structure is shown inFigure 1. Currently, a total of 13 TLRs have been identi ed, among which TLRs 1 10 are expressed in human despite the function of TLR10 is still unclear (Moresco et al., 2011). The expression of TLRs can be found in a variety of immune cells (e.g., dendritic cells, monocytes, macrophages, and B lymphocytes) and non-immune cells (e.g., epithelial cells, endothelial cells, and broblasts;Takeda et al., 2003). While TLR1, TLR2, and TLR4 6 are mainly found on the cell surface, TLR3 and TLR7 9 are primarily expressed in the endosomes (Gay et al., 2014). Two TLRs form a hetero- or homo-dimer that allow them to recognize and bind to di erent molecular patterns (Gay et al., 2014).\nWhen engaging with PAMPs or DAMPs, TLRs can transduce the signaling to initiate innate and adaptive immune responses (Akira and Takeda, 2004; Palm and Medzhitov, 2009). The molecular pathways of TLR signal transduction can be simply categorized into two cascades (Akira and Takeda, 2004; Kawasaki and Kawai, 2014). One is through the main adaptor protein, myeloid di erentiation factor 88 (MyD88). The ligation of TLR ligands results in the recruitment of MyD88 to the TIR domain and subsequently leads to activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and mitogen-associated protein kinase (MAPK), which drive the expression of pro-in ammatory genes. The other is through the adaptor TIR-domain-containing adaptor-inducing interferon-b (TRIF), also known as the MyD88-independent pathway, to activate interferon (IFN) regulatory factors (IRFs) and NF-kB for the production of type I IFNs. Among all human TLRs, TLR3 exclusively signals through TRIF-dependent pathway while others use MyD88-dependent pathway; (Uematsu and Akira, 2007) notably, TLR4 can signal through both pathways in a timedependent manner (Sato et al., 2003; Yamamoto et al., 2003).\nTLR activation is one of the rst defensive mechanisms utilized by the host to mount innate and subsequent adaptive immune responses to ght the invading pathogens and repair the damaged tissues (Takeda and Akira, 2005; Beutler, 2009; Palm and Medzhitov, 2009). However, dysregulated TLR signaling could disrupt the immune homeostasis (i.e., a self-regulating process to remain physiological balance) in the host by sustained pro-in ammatory cytokines and chemokines secretion. This often contributes to the development of many in ammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE), sepsis, atherosclerosis, and asthma (M rshak-Rothstein, 2006; Tsujimoto et al., 2008; Drexler and Foxwell, 2010). Considering the pathological role of TLRs in these in ammatory diseases, inhibitors targeting TLR signaling might be bene cial in treating these disorders (Hennessy et al., 2010).\nDespite many e orts have been put in developing (bio)molecular inhibitors targeting TLR signaling pathways, unfortunately, very few compounds are currently available for clinical uses. Therefore, it is important to search for\nnovel TLR inhibitors that can be utilized both as therapeutic agents and as experimental reagents for dissecting innate immune molecular pathways. Manipulation of immune responsiveness using nanodevices provides a new strategy to treat human diseases, because nanotechnology o ers many bene cial features for therapeutics development, includingcell penetrating and targeting capabilities, desired biodistribution, improved pharmacokinetics, enhanced therapeutic activity, better biocompatibility, andin vivo tracking (bioimaging). Accordingly, novel nanodevices have emerged with bio-activities to potently regulate TLR signaling, aiming for inhibiting disease-associated TLR activation.\nIn this review, we rst brie y summarize the pathophysiological role of TLRs in many diseases of acute and chronic in ammation as well as autoimmunity. These diseases include SLE in autoimmunity, infection-induced spsis for acute in ammation, vascular system disorders across both acute and chronic in ammation, and other in ammationassociated diseases such as psoriasis, gastrointestinal cancer, asthma, and chronic obstructive pulmonary disease (COPD; Table 1). We then focus on the current knowledge in developing TLR antagonists and inhibitors at various stages from preclinical evaluation to clinical trials, including the most recent development of nano-based modulators on inhibition of TLR signaling, and discuss their potential uses in treating various in ammatory diseases. Particularly, we describe the design of these nanodevices and discuss their mechanism(s) of action in TLR inhibition. Due to the unique feature of nanodevices, these nano-inhibitors hold great promises in treating various in ammatory and autoimmune diseases.\nTOLL-LIKE RECEPTOR ACTIVATION IN AUTOIMMUNE AND INFLAMMATORY DISEASES\nSystemic Lupus Erythematosus (SLE) Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the loss of tolerance to self-nuclear antigens and the production of autoantibodies, leading to the attack of the immune system on the self-components and healthy tissues. Recent evidences have suggested a close relationship between the endosomal TLR activation and the onset of SLE (Celhar and Fairhurst, 2014; Wu et al., 2015). It has been found that in B cells and plasmacytoid dendritic cells (pDCs), endosomal TLRs play an essential role in the generation of anti-nuclear antibodies and type I IFNs (Clancy et al., 2016). Particularly, in lupus-prone mouse models, TLR7 overexpression is associated with the production of autoantibodies and the development of autoimmune phenotypes (Pisitkun et al., 2006; Subramanian et al., 2006); on the other hand, in the situation of TLR7 deletion the levels of circulating autoantibodies and in ammatory cytokines, such as IL-6 and INF-a, are signi cantly decreased with improved disease symptoms (Christensen et al., 2006; Lee et al., 2008; Kono et al., 2009). In contrast to TLR7, the role of TLR9 in SLE is not well-de ned. It has been shown that TLR9 is indispensable in the autoantibody production in\nFrontiers in Physiology | www.frontiersin.org 2 July 2017 | Volume 8 | Article 508\nFIGURE 1 | A representative structure of TLR. The conserved structural features of all TLRs consist of three critical components:(1) leucine-rich repeat (LRR) motif; (2) transmembrane helix; (3) intracellular TIR domain. The LRR structure is based on the model of TLR1-TLR2 heterodimer (Protein Data Bank, PDB, ID: 2z7x) interacting with 6 tri-acylated lipopeptides, Pam3CSK4, whereas the TIRdomain homology model is based on TLR2 TIR structure (PDB ID: 1fyw).\nB cells from several mouse studies (Christensen et al., 2006; Nickerson et al., 2010; Chen et al., 2011). However, the absence of TLR9 in these lupus-prone models does not help improve disease conditions, but leads to disease exacerbation (Christensen et al., 2006; Nickerson et al., 2010; Jackson et al., 2014). This suggests that TLR9 may have a regulatory role in the progression of SLE. Nevertheless, the expression of both TLR7 and TLR9 is up-regulated in the peripheral blood mononuclear cells (PBMC) from the SLE patients, and their levels are correlated with the production of IFN-a (Lyn-Cook et al., 2014), making them potential therapeutic targets of SLE.\nIn addition to endosomal TLRs, TLR2 and TLR4 have been found to participate in the pathogenesis of SLE based on the following evidences. First, their mRNA levels in PBMC of SLE patients are much higher than those in healthy controls (Komatsuda et al., 2008; Lee et al., 2016). Second, in a lupus mouse model, the deletion of TLR4 or TLR2 (to a lesser extent) decreases the levels of autoantibodies, and subseqently ameliorates the disease symptoms (Lartigue et al., 2009). Third, the elevation of TLR4 can induce lupus-like autoimmune disease (Liu et al., 2006). All these studies clearly demonstrated the importance of TLR signaling in SLE development and progression.\nInfection-Associated Sepsis Due to their capability of recognizing a variety of PAMPs, TLRs play a critical role in ghting against pathogen infection (Mogensen, 2009). The rst identi ed TLR4 can detect a wide range of Gram-negative bacteria by recognizing and responding to the coating molecules on the bacteria cell wall lipopolysaccharide (LPS). TLR2 (in conjunction with either\nTLR1 or TLR6) primarily recognizes lipoproteins/lipopeptides and glycolipids from various pathogens including microbes and fungi. TLR5 is the only TLR that identi es a protein ligand agellin from nearly all agellated bacteria. On the other hand, the endosomal TLRs (TLR3, and TLR7-TLR9) are mainly responsible for the recognition of nucleic acid ligands, including dsRNA, ssRNA, and CpG-DNA, from viral and intracellular bacterial infection. Therefore, activationf TLRs by engaging with these PAMPs allows the host to combat invading pathogens. In fact, TLR agonists have long been considered as vaccine adjuvants to boost the immune system to eliminate viral infections and most recently ght cancer (O’Neill et al., 2009; Hedayat et al., 2011).\nHowever, excessive and uncontrolled TLR activation can lead to overwhelming systemic in ammation and multiple organ injury, characterized as sepsis. Among all TLRs, TLR2, and TLR4 are the two notable contributors to the pathogenesis of sepsis (Tsujimoto et al., 2008). Evidence came from the observation that the expression of both TLR2 and TLR4 was up-regulated during their ligand stimulation in monocytes from healthy subjects (Wittebole et al., 2005), as well as in PBMC from sepsis patients (Harter et al., 2004). In addition, TLR4 knockout mice are resistant to Gram-negative bacteria-induced septic shock (Roger et al., 2009), and TLR2-de cient mice have increased survival rates compared to wild type mice in a polymicrobial sepsis model (Bergt et al., 2013). Moreover, blockade of TLR2 and TLR4 signaling by antagonistic antibodies successfully decreases disease severity in sepsis models of Gram-positive and Gramnegative bacteria, respectively (Meng et al., 2004; Daubeuf et al., 2007). Interestingly, the protective e ect can also be seen in the TLR3- and TLR9-de cient mice against microbial challenge;\nFrontiers in Physiology | www.frontiersin.org 3 July 2017 | Volume 8 | Article 508\nSLE, systemic lupus erythematosus; IR, ischemia-reperfusion; HSP, heat shock protein; COPD, chronic obstructive pulmonary disease; IBD, in ammatory bowel diseases.\n(Cavassani et al., 2008; Hu et al., 2015) and the pharmacological inhibitors of TLR9 can reduce the mortality of mice in severe sepsis and protect the host from serious complications, such as acute kidney injury (Yasuda et al., 2008; Liu et al., 2012). Since sepsis is one of the leading causes of death in the intensive care units worldwide, much e ort has been put to develop therapeutic agents blocking TLR activation, especially TLR2 and TLR4, although none has yet been clinically successful (see Section Toll-Like Receptor Antagonists/Inhibitors and Their Clinical Applications). Vascular System Disorders Not only can TLRs detect PAMPs in defending pathogen invasion, but they can also recognize circulating host-derived DAMPs released from the dying cells and damaged tissues to trigger the process of self-healing and tissue repair. Till recent\nFrontiers in Physiology | www.frontiersin.org 4 July 2017 | Volume 8 | Article 508\nyears, studies have revealed that sensing the danger signals by TLRs could also contribute to the pathogenesis of many cardiovascular diseases, including atherosclerosis, hypertension, and stroke (Goulopoulou et al., 2016).\nAtherosclerosis nowadays is considered as a chronic, progressive in ammatory condition corresponding to lipid accumulation in the vascular system than simply a lipid buildup disease. It has been found that the onset and ongoing of in ammation is mainly caused by the recognition of oxidized lipoproteins (as DAMPs) by TLRs expressed on innate immune cells (e.g., macrophages) and endothelial cells (Miller, 2005); TLR are also involved in the progression of the disease by lesion orientation (Edfeldt et al., 2002), collagen degradation (Monaco et al., 2009), and plaque destruction (Ishibashi et al., 2013). Speci cally, it has been shown that de ciency in TLR2 or TLR4 results in diminishing in ammation in the prominent mouse models of atherosclerosis [apolipoprotein E (ApoE)- and LDL receptor-de cient mice; (Michelsen et al., 2004; Mullick et al., 2005, 2008; Higashimori et al., 2011)]. The activation of endosomal TLRs, on the other hand, seems to have controversial e ects on atherosclerosis. TLR3 activation has been found to promote atherogenic in ammation, especially in mediating plaque instability (Ishibashi et al., 2013), while the absence of TLR9 exacerbates atherosclerosis in ApoE-de cient mice on a high-fat diet (Koulis et al., 2014).\nIn the case of hypertension, TLR4 has been well-documented to mediate aberrant immune and in ammation in vasculature, kidneys and autonomic nervous system (McCarthy et al., 2014). This is mainly because TLR4 can respond to angiotensin II, a DAMP, and cause subsequent vascular dysfunction and high blood pressure (Bom m et al., 2015; Hernanz et al., 2015). Surprisingly, the evidence of TLR2 involved in hypertension is limited to in ammation in the renal system, where TLR2activated NF-kB signaling is signi cantly correlated with renal ischemia/reperfusion injury (Khan et al., 2012). Recently, attentions have been drawn to TLR9 for its role in hypertension and blood pressure regulation. Studies have shown that TLR9 activation could elevate blood pressure in normotensive rats (McCarthy et al., 2015), and could also serve as a negative modulator of cardiac autonomic tone and barore ex function (Rodrigues et al., 2015).\nTLR2, TLR4, and endosomal TLRs have all been found to play an important role in stroke and cerebrovascular injury. Interestingly, most of them have a dual function along the time course of the disease: activation of TLRs in post-ischemia state would mediate neuroin ammation and neurodegeneration, but preconditioning with TLR stimulation could be neuroprotective from hypoxia and nutrient deprivation (Wang et al., 2011; Gesuete et al., 2014). For example, TLR7 and TLR8 expression is correlated to the aggravated neuroin ammation and poor outcome in acute ischemic stroke patients (Brea et al., 2011). On the other hand, TLR7 preconditioning [i.e., pretreatment with a TLR7 agonist, gardiquimod (GDQ), prior to ischemia] has shown protection against subsequent stroke injury through type I IFN-mediated mechanism (Leung et al., 2012).\nOther In ammatory Diseases Activation of TLRs is also involved in many other in ammationassociated diseases, such as psoriasis, gastrointestinal malignancies, and in ammatory airway diseases. Their relationships are brie y described hereafter.\nPsoriasis is a long-lasting, relapsing in ammatory disease of dermis and epidermis. It has been observed that the expression f transforming growth factor (TGF)-a and heat shock proteins (e.g., HSP60) from keratinocytes can upregulate TLR5 and TLR9 (Miller et al., 2005), and activate TLR2 and TLR4, respectively (Seung et al., 2007). In addition, activation of TLR7/8 by its speci c agonist imiquimod could also aggravate the disease symptoms (Gilliet et al., 2004).\nIt is known nowadays that chronic in ammation is often linked to carcinogenesis. In particular, chronic gastritisdue to Helicobacer pyloriinfection and severe colitis of patients with in ammatory bowel diseases (IBD) greatly increase the riskof having gastrointestinal malignancies (Itzkowitz and Yio, 2004; Houghton and Wang, 2005), and TLR signaling is evidently involved in such in ammatory complications (Fukata and Abreu, 2008). It has been found that TLR4/MyD88 pathway can promote the development of colitis-associated colorectal tumors (Fukata et al., 2007). Since tumor cells also express TLR4, TLR4-induced uncontrolled production of immunosuppressive cytokines has been suggested to contribute to the tumor progression (Sato et al., 2009).\nIn in ammatory airway diseases, such as asthma and COPD, TLR signaling pathways are closely linked to the disease pathophysiology (Bezemer et al., 2012). For examples, house dust mites, one of the main risk factors for allergic asthma has been suggested to trigger airway neutrophils and monocytes through a TLR4-dependent mechanism (Li et al., 2010). Furthermore, the TLR4 agonist LPS is able to induce either Th1 or Th2 immune response in asthma in a dose dependent manner (Dong et al., 2009). In the case of COPD, TLR2, TLR4, and TLR9 have been shown to participate in cigarette smoke-induced in ammatory responses (Droemann et al., 2005; Karimi et al., 2006; Mortaz et al., 2010). During the exacerbation of the airway diseases, overactive TLR signaling can contribute to excessive in ammatory responses and lung tissue destruction (Tokairin et al., 2008; Stowell et al., 2009).\nTOLL-LIKE RECEPTOR ANTAGONISTS/INHIBITORS AND THEIR CLINICAL APPLICATIONS\nAlthough, evolutionarily TLRs are essential elements in innate immune system and play a critical role in the host defensive mechanism against invading pathogens, overactivation of TLRs is inevitably involved in the pathogenesis of many in ammatory diseases. Thus, inhibition of TLR signaling pathways has been predicted to be an e ective therapeutic strategy to suppress unwanted, disease-associated in ammatory responses. In general, TLR inhibition can be achieved by two major strategies: (1) blocking the binding of TLR ligands to the receptor; (2) interfering the intracellular signaling pathways to stopthe\nFrontiers in Physiology | www.frontiersin.org 5 July 2017 | Volume 8 | Article 508\nsignal transduction (Figure 2). Accordingly, various therapeutic agents for inhibiting TLR signaling have been developed to control excessive in ammation; they can be classi ed as small molecule inhibitors, antibodies, oligonucleotides, lipid-A analogs, microRNAs, and new emerging nano-inhibitors. The current advances of each class are summarized and discussed hereafter (Tables 2 5).\nSmall Molecule Inhibitors (SMIs) Small molecule inhibitors (SMIs) are synthetic or naturally derived chemical agents with the activity to inhibit TLR signal transduction. Their amphipathic property and small size allow them to cross cell membranes and act on speci c intracellular adapter proteins or compartments along the TLR signaling pathways. They usually have good bioavailability but poor speci city and targeting capability. The ease of manufacturing and handling of SMIs makes them popular drug candidates in pharmaceutical industries (Table 2). In the clinical practice, a group of antimalarial drugs, including hydroxychloroquine sulfate (HCQ), chloroquine (CQ), and quinacrine (or mepacrine), have been used to treat autoimmune diseases (arthritis and SLE) after World War II (Fox, 1996; Ruiz-Irastorza et al., 2010). It was not until recent years that their additional mechanisms of action on endosomal TLR signaling (TLR7/8/9) was identi ed (Kuznik et al., 2011; Lee et al., 2011). These SMIs are all weak bases and tend to accumulate in the acidic intracellular compartments like\nendosomes and lysosomes, and are able to modulate the pH in these vesicles. The pH modulation can lead to suppression of autoantigen presentation, blockade of endosomal TLR signaling, and decrease in cytokine production (Fox, 1996; Wozniacka et al., 2006; Kuznik et al., 2011). Other mechanisms include inhibition of MAPK signaling and phospholipase A2, antiproliferation, photoprotection as well as reduction of matrix metalloproteinase-9 (MMP-9) activity (Lo er et al., 1985; Weber et al., 2002; Kim et al., 2006; Wozniacka et al., 2008; Lesiak et al., 2010). These mechanisms of action altogether suggest their anti-in ammatory and immuno-suppressive activity.\nIn addition to autoimmune diseases, these SMIs of TLR7/8/9 are also under investigation in other diseases associated with uncontrolled acute or chronic in ammation. For example, the antimalarial drug CQ has shown its clinical potential in treating severe sepsis, especially in reducing the risk of sepsis-induced acute renal failure (Yasuda et al., 2008). For its capability of blocking endosomal acidi cation and anti-in ammation, CQ has been applied to prevent and treat various viral infections, such as HIV, in uenza, and dengue (Paton et al., 2011; Borges et al., 2013). In pre-clinical studies, CQ pretreatment can signi cantly improve the cerebral ischemia symptoms in a transient global cerebral ischemia rat model, which suggests that these SMIs of endosomal TLRs could be bene cial for patients with cardiovascular diseases (Cui et al., 2013). Moreover, longterm administration of HCQ has been found to ameliorate\nFIGURE 2 | Potential drug targets of TLR signaling pathways. The TLR inhibition can be achieved through two major strategies: (1) blocking the binding of the agonists to the corresponding TLRs, and (2) inhibiting the intracellular signaling of the TLR pathways. The antibodies, lipid A analogs and oligonucleotides primarily target at the ligand-receptor binding, whereas the microRNAs (miRNAs) mainly act on the intracellular signaling cascades of TLR pathways; the small molecule inhibitors (SMIs) can inhibitor TLR signaling through both strategies.\nFrontiers in Physiology | www.frontiersin.org 6 July 2017 | Volume 8 | Article 508\nARB, angiotensin II receptor blocker; CQ, chloroquine; HCQ, hydroxychloroquine; RA, rheumatoid arthritis; SLE, systemic lupus erythematosu ; IND, investigational new drug application. aStudy terminated. bUnknown status. cCompleted with unknown results. 1Clinical drugs with new applications.\nRA, rheumatoid arthritis.\nSLE, systemic lupus erythematosus. aStudy discontinued. bCompleted with unknown results.\nFrontiers in Physiology | www.frontiersin.org 7 July 2017 | Volume 8 | Article 508\nSLE. systemic lupus erythematosus; NAHNP, non-anticoagulant heparin nanoparticle; HDL, high-density lipoprotein; NP, nanoparticle; GNP, goldnanoparticle. aStudy discontinued.\nhypertension and aortic endothelial dysfunction in a lupus animal model (Gomez-Guzman et al., 2014). These evidences highlight the great potential of the early developed antimalari drugs and their derivatives as endosomal TLR SMIs in treatinga wide range of in ammatory and autoimmune diseases.\nFollowing the success of these early antimalarial drugs, new SMIs have been developed to target endosomal TLR7/8/9 signaling. Among these newly developments, CpG-52364 is a quinacrine derivative, a SMI of TLR7/8/9 (Lipford et al., 2007). Comparing to HCQ, CpG-52364 is more therapeutically e ective and has less side e ects from animal studies; a phase I clinical trial was completed in 2009 for SLE treatment (P zer: NCT00547014), but the results have not been released since. Another exciting advancement is SM934, a novel analog of artemisinin (or qinghao su, the new antimalarial drug identi ed in the early-70’s in China), targeting TLR7/9. Studies have shown the therapeutic e ects of the orally administered SM934 on lupus-prone MRL/lpr mice by inhibiting Th1 and Th17 cell responses as well as suppressing the B cell activation and plasma cell production (Hou et al., 2011; Wu et al., 2016). ST2825 is a peptidomimetic compound with an inhibitory activity on the MyD88 dimerization and recruitment of interleukin1 receptor-associated kinase 1 (IRAK1) and IRAK4 (Loiarro et al., 2007); it has been found to suppress TLR9-induced B cell proliferation and di erentiation into plasma cells as well as autoantibody production (Capolunghi et al., 2010). Although ST2825 is primarily used as an experimental agent, it provides evidence of inhibiting MyD88 (the universal adaptor used by most TLRs except TLR3) as a potential therapeutic target to treat patients with SLE and possible other autoimmune diseases.\nIn addition to endosomal TLR signaling, TLR2 and TLR4 are other two major targets of therapeutic SMIs. TAK-242 (Resatorvid) is an anti-sepsis SMI that targets TLR4 signaling pathways (Matsunaga et al., 2011). This compound binds to cysteine 747 in the intracellular TIR domain of TLR4, which blocks the interaction between TLR4 and the adaptor\nproteins-TIR domain containing adaptor protein (TIRAP) and TRIF-related adaptor molecule (TRAM), thereby diminishing LPS-induced TLR4 signaling and in ammation. Based on its preclinical success, TAK-242 advanced into clinical investigations. Two phase III clinical trials NCT00143611 for severe sepsis and NCT00633477 for sepsis-induced cardiovascular and respiratory failure were launched. In the rst trial, the results were unfortunately not satisfactory due to failure to e ectively suppress serum cytokine levels (IL-6, IL-8, and TNFa) comparing to controls, even though the drug was well-tolerated (Rice et al., 2010). The second trial, however, was terminated due to a business decision, and no further clinical development of TAK242 has been conducted ever since.\nLike antimalarial drugs, angiotensin II receptor blockers (ARBs), and statins are among the early developed drugs with newly discovered inhibitory activity on TLR2 and TLR4 signaling. For example, the ARB family valsartan can decrease proin ammatory cytokines release and infarct size by inhibiting TLR4 signaling (Yang et al., 2009) while candesartan can suppress Pam3CSK4 and LPS induced TLR2 and TLR4 activation, respectively (Dasu et al., 2009). Statins, also known as 3- hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are a class of lipid-lowering drugs. Among the statin family, uvastatin, simvastatin, and atorvastatin all have shown potent inhibitory activity on TLR4 and subsequent in ammatory pathways to reduce in ammation in vascular systems (Methe et al., 2005; Foldes et al., 2008; Fang et al., 2014).\nAntibodies Due to their high speci city, antibodies have been widely used as biological tools to precisely probe certain molecules. For therapeutic applications, they can be designed to neutralize soluble e ectors, block the binding of receptors to their ligands to stop signal transduction, or induce targeted cytotoxicity(Suzuki et al., 2015). The most attractive feature of therapeutic antibodies is their superior speci city to the drug targets comparing to\nFrontiers in Physiology | www.frontiersin.org 8 July 2017 | Volume 8 | Article 508\nother type of drugs, and hence they are getting great attentions especially for immunotherapy nowadays. However, antibodies still possess a number of limitations including high costs in manufacturing, poor cellular and tissue penetration, and risks of immunogenicity (Chames et al., 2009).\nIn terms of inhibiting TLR signaling, antibodies are designed (as antagonists) to block the binding of ligands to the speci c TLRs (Table 3). One promising advancement is OPN305, which is the rst fully humanized IgG4 monoclonal TLR2-speci c antibody. Pre-clinical studies have shown the potency of this compound in blocking TLR2-mediated proin ammatory cytokine production in vitro and in ischemiareperfusion (IR) injury animal models (Ultaigh et al., 2011; Arslan et al., 2012; Farrar et al., 2012). The success of OPN305 in phase I study suggests that OPN-305 is an e ective and well-tolerated treatment for the prevention of IR injury in solid organ transplantation (Reilly et al., 2013). It is currently under a phase II clinical trial (NCT01794663) in renal transplant patients with a high risk of developing delayed graft function.\nT2.5 is another anti-TLR2 antibody with therapeutic potential. It was found to increase animal survival and protect against severe shock-like syndrome in a mouse model challenged with Pam3CSK4 (a TLR1/2 ligand) or lethally challenged withBacillus subtilis(Meng et al., 2004). A combination therapy of T2.5 with 1A6 (an anti-TLR4 antibody, see below) have shown bene cial e ects in a sepsis mouse model challenged byS. entericaand E. coli(Spiller et al., 2008). In addition to sepsis models, T2.5 treatment was able to decrease neural death and in ammatory responses in a model of transient brain ischemia (Ziegler et al., 2011). Moreover, T2.5 was found to prevent angiotensin II-induced cardiac brosis through suppressing macrophage recruitment and in ammation in the heart (Wang et al., 2014). Altogether, these proof-of-principle studies suggest that blocking TLR2 signaling is therapeutically bene cial to sepsis and vascul r system disorders. However, this compound was not moved forward into clinical development but remains as a widely used experimental tool now.\nNI-0101 is the rst monoclonal anti-TLR4 antibody entering clinical development. It can potently inhibit TLR4 signaling by blocking TLR4 dimerization, which is independent on the ligand type and concentration (Monnet et al., 2015). NI0101 just completed a phase I clinical trial (NCT01808469) and the results were very encouraging (Monnet et al., 2017). NI-0101 was well-tolerated without safety concerns at various doses; it could successfully block cytokine releasx vivo and in vivo, and prevent u-like symptoms upon LPS administration. Recent data demonstrated that NI-0101 could also block rheumatoid arthritis (RA) synovial uids-induced pro-in ammatory cytokine production in monocytes isolated from RA patients (Hatterer et al., 2016). Now, the company is preparing for a phase II clinical trial in RA patients with a TLR4-driven pathotype in 2017.\nAnother monoclonal antibody of TLR4 is 1A6, which targets the extracellular portion of the TLR4-myeloid di erentiation factor 2 (MD2, a co-receptor for TLR4 activation) complex (Spiller et al., 2008). In preclinical study, 1A6 showed protective\ne ect on microbial-induced septic shockin vivo (Spiller et al., 2008; Lima et al., 2015). Interestingly, in a mouse model of dextran sulfate sodium (DSS)-induced colitis, 1A6 could ameliorate in ammation and prevent the progression of the intestine in ammation; however, the blockade of TLR4 signali g by 1A6 could also cause a defect in the mucosal healing during the recovery stage (Ungaro et al., 2009). This study perhaps sent a warning message of blocking early TLR4 signaling as potential therapy for in ammatory bowel diseases (IBD); on the other hand, it provided a strong evidence of multiple roles of TLRs in disease development, progression and remission, guiding the development of next generation of therapeutic TLR inhibitors.\nOligonucleotides Since endosomal TLRs primarily recognize nucleic acid structures from dsRNA, ssRNA, and CpG-DNA, oligonucleotides with certain sequences are predicted to function as antagonists of endosomal TLRs. They can interfere the binding of endosomal TLRs to their ligands, and hence block the TLR signal transduction. Accordingly, several oligonucleotidebased TLR antagonists have been developed particularly to reat in ammatory diseases associated with endosomal TLR activation, such as SLE; each is discussed hereafter (Table 4). One of the leading developments of oligonucleotide-based TLR antagonists is named immunoregulatory DNA sequence (IRS; by Dynavax Technologies). Advancing from the earlier encouraging prototypes, IRS-661 (TLR7 speci c) and IRS-869 (TLR9 speci c), a dual-function targeting both TLR7 and TLR9 antagonist, IRS-954 was developed for the treatment of SLE (Barrat et al., 2005). IRS-954 was found to inhibit IFNa production by human plasmacytoid predendritic cells in response to DNA or RNA of viruses and immune complexes from SLE patients. In addition, IRS-954 treatment showed a reduction of autoantibodies and improvement of disease symptoms in lupus-prone mice (Barrat et al., 2007). Furthermore, it could also reverse TLR7/9-mediated glucocorticoid resistance of SLE, and thus could be potentially used as corticosteroid-sparing drug (Guiducci et al., 2010). Although IRS-954 has shown promising pre-clinical therapeutic e cacy, there is no further advancemnt documented in the clinical development to date. On the other hand, DV-1179, another TLR7/9 dual antagonist developed by the same company, entered a phase Ib/IIa study (in partner with GSK) for its safety in both healthy volunteers and patients with active SLE (Dynavax, 2014). Although DV-1179 administration was well tolerated, it failed to achieve the endpoints of reducing the IFN-a-regulated genes1. Such an unfortunate outcome ended the clinical development of this compound ever since.\nAnother development of oligonucleotide-based antagonists (also termed as immune modulatory oligonucleotide IMO) has made some success into clinical trials (by Idera Pharmaceuticals). The compound IMO-3100 is also a TLR7/9 dual antagonist. In preclinical studies, IMO-3100 could signi cantly reduce the expression of in ammatory genes, such as IL-17A,b-defensin,\n1http://www.streetinsider.com/Corporate+News/...DV1179.../972 788.html\nFrontiers in Physiology | www.frontiersin.org 9 July 2017 | Volume 8 | Article 508\nCXCL1, and keratin 16 in a mice model of IL-23-induced psoriasis (Suarez-Farinas et al., 2013). Moreover, this compound showed an inhibitory activity on disease progression in a lupusprone mice model (Zhu et al., 2011). A phase II trial for the treatment of psoriasis was completed in 2012 (NCT01622348), but the results have not yet been disclosed. IMO-8400 is another candidate under current development. Di erent from IMO-3100, IMO-8400 is capable of inhibiting all TLR7, TLR8, and TLR9. This compound was very e ective in preventing in ammation and disease development in both lupus and psoriasis mouse models (Jiang et al., 2012; Zhu et al., 2012; Suarez-Farinas et al., 2013). Currently, two phase II clinical trials are underway for the treatment of plaque psoriasis (NCT01899729) and dermatomyositis (NCT02612857). Similar to IMO-8400, a newly developed IMO-9200 can also target TLR7/8/9. From a phase I clinical trial (in partner with Vivelix), it showed a safe and well-tolerated pro le in healthy subjects2.\nThere are other immunoregulatory oligonucleotides under preclinical developments. The inhibitory oligonucleotide (IHNODN) 2088 is a potent TLR9 antagonist. In spontaneously hypertensive rats, IHN-ODN 2088 treatment showed positive e ects on systolic blood pressure reduction (McCarthy et al., 2015). Based on IHN-ODN 2088, a guanine-modi ed inhibitory oligonucleotide, INH-ODN-24888, was designed; this compound demonstrated a promising therapeutic e ect in SLE through the suppression of both TLR7 and TLR9 (Rommler et al., 2015). The guanine modi cation potentiates the inhibitory activity of INH-ODN-24888 and e ciently improves its capacity to reduce TLR7/9-mediated immune signaling in human immune cells (Rommler et al., 2013). These results indicates that IHNODN-24888 may be further developed into a promising clinical treatment for SLE.\nLipid A Analogs A special group of TLR antagonists is the lipid A analog (Table 5), speci cally targeting TLR4. Lipid A is a lipid component of LPS (or endotoxin) contributing to the toxicity of an endotoxin molecule. Because the structure of lipid A is highly conserved in endotoxins, it becomes an attractive therapeutic target to regulate TLR4 signaling (Rietschel et al., 1994).\nA synthetic lipid A analog ofRhodobacter sphaeroides, eritoran (E5564), is probably the most exciting but also disappointing clinical development of TLR4 antagonist (by Eisai Research Institute of Boston Inc.) (Barochia et al., 2011). Eritoran is the 2nd generation of its own kind derived from the rst developed E5531 (Christ et al., 1995). The design principle of these compounds was to competitively bind to the MD2 pocket by mimicking the lipid A structure, which in turn prevents the LPS binding and the induction of TLR4 signaling (Park et al., 2009). The structural improvement of eritoran makes it superior to E5531 for its higher potency due to extended duration of action, cost-e ective manufacturing because of a simpler structure, greater water solubility, and better chemical st bility. Preclinically, eritoran could signi cantly reduce LPS-induced NF-kB activation and pro-in ammatory cytokine production\n2http://vivelix.com/research-and-development/\n(TNF-a, IL-1b, IL-6, and IL-8) in vitro and in animal models (Mullarkey et al., 2003; Savov et al., 2005). In a phase I clinical study on LPS challenged healthy volunteers, eritoran treatm n e ectively decreased TNF-a and IL-6 levels in the blood, reduced the white blood cell counts and C-reactive protein levels, and diminished sepsis-associate clinical symptoms; the only observed adverse response was the dose-dependent phlebitis (Lynn et al., 2004; Rossignol et al., 2004, 2008). It then went on a randomized, double-blind, multicenter phase II trial (NCT00046072) to treat critically ill septic patients with high predicted risk of mortality; the results were positive as the intravenous treatment of eritoran at the dose of 105 mg led to a trend toward a lower mortality rate (Tidswell et al., 2010). Sadly, the phase III trial (ACCESS, NCT00334828) of eritoran on severe sepsis patients failed because eritoran did not reduce the patient mortality at 28 days and 1 year from the statistical analysis (Opal et al., 2013). Accordingly, the company decided to give up launching the drug to the market.\nAlthough the development of eritoran led to a disappointing end, valuable lessons can be learned from this failed practice for developing the next generation of TLR inhibitors. First,the patient recruitment is key to objectively evaluate the drug e cacy in a clinical trial. One major reason that eritoran failed inthe ACCESS was probably because the recruited patients were not well-assessed according to their disease pathogenesis, particularly the circulating levels of LPS in the patients. This is a critical factor that should be included in the recruiting criteria. Since the mechanism of eritoran is to block LPS binding to TLR4, those patients who had low levels of circulating LPS at the time of studies may not respond well to the treatment, and thus contributed to an overall null e cacy of the drug. Second, the time and route of drug administration need to be optimized. Considering the acute in ammatory responses in sepsis, the timing of eritoran administration could be too late to be therapeutic e ective when other in ammatory mediators started to take over. Third, the genetic backgrounds, the infectionstatus, and the disease severity all contributed to the heterogeneity in the patients, which ultimately resulted in di erent responses toward the treatment. Finally, the in ammatory responses ofthe septic patients could be triggered by multiple TLR pathways, and blocking one of them (even though TLR4 has been considered the major one) may not be enough to stop the overwhelming in ammation in severe sepsis. To ensure future success in developing new TLR inhibitors for in ammatory diseases like sepsis, perhaps new inhibitory strategy on multiple TLR pathways should be considered; and clearly in the clinical trials, patients should be carefully selected and examined based on appropriate criteria with well-de ned biomarkers to obtain the fair evalu tion and interpretation of the therapeutic e cacy of the tested drugs.\nApart from treating sepsis, eritoran could still be therapeutically bene cial for other in ammatory diseases. In fact, one study has shown that eritoran could prevent in uenza-induced death in a mouse model, where it improved the clinical symptoms, inhibited cytokine production (TNF-a, IL-1b, CXCL1, and IL-6), and reduced viral titers (Shirey et al., 2013). Other studies have shown the therapeutic e cacy\nFrontiers in Physiology | www.frontiersin.org 10 July 2017 | Volume 8 | Article 508\nof eritoran in several cardiovascular disease models. For example, eritoran could reduce cardiac hypertrophy in an aortic constriction mouse model (Ehrentraut et al., 2011), and attenuate in ammatory cytokine production and myocardial IR injury in a rat model (Shimamoto et al., 2006). In addition, eritoran has also provided protective e ects on kidney IR injury (Liu et al., 2010). Unexpectedly, it has also been suggested that eritoran could potentially overcome the blood-brain barrier under cetain in amed conditions (like stoke) and play an advantageous role in treating cerebral infarction (Buchanan et al., 2010).\nmiRNA Inhibitors MicroRNAs (miRNAs) are small ( 22 nucleotides), endogenous non-coding RNAs with post-transcriptional regulatory functions to nely tune gene expression (Bartel, 2009). They bind to a target sequence in the 30-untranslated region (UTR) of the messenger RNA (mRNA) to facilitate mRNA degradation or inhibit its translation. Since miRNAs are involved in the regulation of diverse biological processes and associated with pathogenesis of many diseases, they have emerged as new therapeutic targets.\nTill now, there are about 20 miRNAs identi ed to be involved in the regulation of TLR signaling pathways (He et al., 2014). Among them, miR-146a, miR-155, and miR-21 are the three miRNAs received extensive attention for their regulatory roles in TLR signaling and autoimmune diseases (Table 5; Quinn and O’Neill, 2011; Shen et al., 2012). MiR-146a was identi ed from a screen of LPS-responsive genes regulated by NF-kB; it was found to inhibit the translation of the TNF receptorassociated family 6 (TRAF6) and IRAK1, both of which are in the downstream pathway of TLR4 signaling (Taganov et al., 2006). Further studies have shown that miR-146a could play a negative regulatory role in autoimmunity (Boldin et al., 2011), particularly in blocking the type I IFN production in human lupus by targeting TLR-type I IFN associated genes TRAF6, IRAK1, IFN regulatory factor 5 (IRF5), and signal transducer and activator of transcription 1 (STAT1;Tang et al., 2009). Given the fact that miR-146a acts on multiple targets in the signaling cascades of TLR-mediated induction of type I IFN, the integrated e ects of negative regulation by miR-146a on the pathway are expected to be bene cial in treating SLE and perhaps RA. To translate miR-146a into clinic uses, one possible way is to apply a delivery vehicle to help miR-146a cross the cell membranes in order to function intracellularly (Pan et al., 2012).\nBoth miR-21 and miR-155 were originally identi ed as onco-miR, but later discovered to have a new role in regulating TLR signaling and in ammation. They were found to be upregulated in TLR-associated in ammatory conditions (O’Connell et al., 2007; Sheedy et al., 2010). Speci cally, miR-21 could enhance the LPS-induced anti-in ammatory cytokine IL-10 production by lowering programed cell death 4 gene (PDCD4) expression, serving as a negative regulator of the in ammatory response (Sheedy et al., 2010). MiR-155, on the other hand, appears to have controversial roles in controlling in ammation. In one study, miR-155 targeted TGFb activated kinase 1 (TAK1) binding protein 2 (TAB2) and\ninhibited TAK1 activation, which subsequently blocked the activation of downstream NF-kB and MAPK pathways, and dampened the in ammatory responses (Ceppi et al., 2009). Another study reported that miR-155 expression contributed to the production of the proin ammatory cytokine TNF-a and increased the susceptibility to septic shock (Tili et al., 2007). In addition, miR-155 was found to have a positive e ect in the pathogenesis of SLE, as miR-155 knockout mice had phenotypes similar to some human systemic autoimmune disorders, and were highly resistant to experimental autoimmune encephalomyelitis, a SLE mouse models (O’Connell et al., 2010). Accordingly, a miR-155 antagonist, MRG-107, is currently under preclinical development (by miRagen Therapeutics) to treat neuro-in ammation.\nNew Emerging Nano-Inhibitors In addition to above described inhibitors/antagonists, nanodevices are emerging as a new class of potent TLR inhibitors that can target a single or multiple TLR pathways (Table 5). Due to their nanoscale sizes, nano-inhibitors are expected to have better bio-distribution and sustained circulation (He et al., 2010; Blanco et al., 2015). They can be functionalized to meet the desired pharmacodynamic and pharmacokinetic pro les (Ernsting et al., 2013; Lin and Tam, 2015). One distinct feature of these new nano-inhibitors is that the bio-activity comesfrom their self-properties, which can be tailored to di erent medical complications, rather from a carried therapeutic agent. This characteristic makes them a special class of drug (or nanodrug ) as the next generation nano-therapeutics. Currently, they are at the preclinical investigation stage.Figure 3 summarizes their targets in the TLR pathways, whereas their structures, physicochemical properties and mechanisms of action are listed in Table 6.\nOne interesting immunomodulatory nanodevice is the lipidconjugated non-anticoagulant heparin nanoparticle (NAHNP; Babazada et al., 2014a,b). In addition to its well-known anticoagulant function, heparin is known to have anti-in ammatory activity for its ability to bind and inhibit various cytokines, growth factors and enzymes that are involved in in ammation (Tyrrell et al., 1999); especially, the 6-O sulfation of glucosamine r sidues of heparin can block the binding of P- and L-selectins for the recruitment of leukocytes at in ammatory sites (Wang et al., 2002). Being intrigued by the intrinsic anti-in ammatory properties of heparin, Babazada et al. synthesized the glycol-split non-anticoagulant heparin with D-erythro-sphingosine grafts, which can self-assemble into NAHNP (Babazada et al., 2014b). These nanoparticles (NPs) were found to suppress LPS-induced MyD88-dependent NF-kB activation and inhibit subsequent cytokines production in mouse macrophages. They further discovered that the length of the alkyl chains of conjugated D-erythro-sphingosine was critical for the anti-in ammatory activity as shortening the alkyl chain of NAHNP resulted in loss of activity. Again, the 6-O-sulfate groups of d-glucosamine residue were important for such an inhibitory activity. By removing the anti-coagulant activity of heparin, NAHNP could serve as new anti-in ammatory nano-therapeutics.\nFrontiers in Physiology | www.frontiersin.org 11 July 2017 | Volume 8 | Article 508\nFIGURE 3 | The mechanisms of action of emerging nano-inhibitors targeting TLR signaling pathways. The HDL-like NP is capable of sequestering LPS to down-regulate TLR4 signaling; NAHNP and 11-NP can block theLPS binding to TLR4-MD2 complex, and thus inhibit TLR4 signal transduction; bare gold nanoparticle (GNP) is able to down-regulate TLR4 expression; the peptide-gold nanoparticle hybrid P12 can inhibit multipleTLR pathways including TLR2, 3, 4 and 5, and block the endosomal acidi cation. These nano-inhibitors can eventually down-regulate the transcription factors NF-kB and IRF activation, leading to the inhibition of the production of in ammatory cytokines and type I interferons.\nAnother novel nanodevice, the high-density lipoprotein (HDL)-like nanoparticle (HDL-like NP), was developed as a TLR4 antagonist by sequestering LPS (Foit and Thaxton, 2016). HDL has been known to naturally bind to and neutralize LPS (Brandenburg et al., 2002), and has been applied to reduce LPSinduced in ammation in vivo (Pajkrt et al., 1996; Guo et al., 2013). The HDL-like NP was designed with a gold NP core and a HDL coating, where the lipid components of HDL can be modi ed (Foit and Thaxton, 2016). Through screening ve variants of the lipid coatings, one HDL-like NP was identi edto be able to potently inhibit TLR4 signaling triggered by various sources of LPS and Gram-negative bacteria on human cell lines and PBMC. As expected, the acting mechanism of this HDLlike NP was through scavenging the LPS molecules. It is worth noting that this newly synthesized HDL-like NP exhibits much higher anti-in ammatory activity than the HDL alone, making it a promising candidate as a next generation nano-antagonist of TLR4.\nGold nanoparticles (GNPs) have caught much attention as emerging nanotheranostics in nanomedicine, owing to theirease of fabrication and functionalization, chemical stability, excellent photothermal physical properties, and good biocompatibility (Pedrosa et al., 2015). The fact that a TNF-a-bound GNP\nagent (CYT-6091 by CytImmune Sciences) showed very-well tolerated pro le in a phase I clinical trial warrants the potential clinical uses of GNP-based therapeutics in the near future (Libutti et al., 2010). The exciting advancement in the eld is the development of GNP-based nano-inhibitors for TLR signaling. In one study, bare GNP was applied as the posttreatment topically to ameliorate LPS-induced eye in ammatory responses and reduce the oxidative damage in irides (Pereira et al., 2012). The possible mechanism was through downregulating TLR4 expression and the corresponding LPS-induced NF-kB activation. This discovery is quite surprising as the bare GNP is physiologically unstable, and is usually thought to be inert without biological activity. It would be interesting tosee the follow-up study and the detailed working mechanisms of bare GNP. In another study, a cationic glycolipid-coated GNP system was developed as a new TLR4 antagonist (Rodriguez Lavado et al., 2014). A new class of glycolipids was synthesized to have a structure mimicking lipid A binding to CD14 and the TLR-MD2 pocket. The biological analysis showed that the GNP coated with a speci c glycolipid (11-NP) was able to inhibit the LPS-induced TLR4-MD2 activation in human and murine cells; such an e ect was similar to the very e cient TLR4 antagonist eritoran. Further studies on the structure-activity relationship analysis indicated that the presence of fatty ester chains andthe facial amphiphilicity of the glycolipids are required to maintain TLR4 antagonistic activity. Preliminaryin vivo studies showed that 11-NP was very e ective in reducing TNF-a level in the blood in a LPS mouse model.\nOne exciting invention is the development of a completely novel peptide-GNP hybrid system as a next generation nanoinhibitor led by Yang et al. (2015, 2016). The system is made of a GNP core coated with a hexapeptide layer to enhance the physiological stability of the GNP, change the surface physicochemical characteristics, and enable the biological activity (Yang et al., 2011, 2013). Through, screening a small library of the established, physiologically stable peptide-GNP hybrids, they discovered a potent multi-TLRs inhibitor, P12, which not only suppressed both arms of TLR4 signaling (i.e., MyD88dependent NF-kB and TRIF-dependent IRF3 activation), but also inhibited TLR2, TLR3, and TLR5 pathways. The structureactivity relationship analysis revealed that the activity index is strongly dependent on the surface properties of the hybrid, where the hydrophobicity and the aromatic ring-like structure arethe two key factors dictating the inhibitory activity (Yang et al., 2015). Further studies conferred the anti-in ammatory activity of P12 in correcting LPS-induced gene expressions, reducingthe subsequent pro-in ammatory cytokine production (IL-12p40, MCP-1, and IFN-g), and increasing the anti-in ammatory cytokine IL-1RA. In searching for the mechanism of action, delicate experiments were performed to show that the potent inhibitory activity of P12 is mainly due to its endosomal pH modulation capability (Yang et al., 2016). Like chloroquine (CQ), a lysotropic agent that can elevate endosome/lysosome pH, P12 was able to prevent the endosomal acidi cation process, which in turn attenuated downstream signal transduction of endosomal-dependent TLR signaling. More importantly, the inhibitory activity of the nano-drug can be well-tuned by\nFrontiers in Physiology | www.frontiersin.org 12 July 2017 | Volume 8 | Article 508\nTA B\nLE 6\n| T\nhe st\nru ct\nur es\n,p hy\nsi co\nch em\nic al\npr op\ner tie\ns, an\nd m\nec ha\nni sm\ns of\nth e\nno ve\nlT LR\nna no\n-in hi\nbi to\nrs .\nC om\npo un\nd N\nA H\nN P\nH D\nLlik\ne N\nP B\nar e\nG N\nP G\nly co\nlip id\n-c oa\nte d\nG N\nP P\ne pt\nid e-\nG N\nP hy\nbr id\nS tr\nuc tu\nre\nS iz\ne 11\n0 16\n0 nm\n15\nnm\n30 nm\nN /A\n15\nnm\nN P\nfo rm\nat io\nn S\nel f-\nas se\nm bl\nin g\nS ur\nfa ce\nco at\nin g\non G\nN P\nG N\nP on\nly (c\nitr at\ne coa\nte d)\nS ur\nfa ce\nco at\nin g\non G\nN P\nS ur\nfa ce\nco at\nin g\non G\nN P\nS ur\nfa ce\nch ar\nge N\neg at\niv e\nN eg\nat iv\ne N\neg at\niv e\nP os\niti ve\nN eg\nat iv\ne\nB io\nde gr\nad ab\nili ty\nP os\nsi bl\ne N\no N\no N\no N\no\nM ec\nha ni\nsm s\nof ac\ntio n\nIn te\nra ct\nio n\nw ith\nT LR\n4/ M\nD 2\nco m\npl ex\nN eu\ntr al\niz at\nio n\nof LP\nS D\nec re\nas e\nin T\nLR 4\nan d\nN F\n-k B\nex pr\nes si\non B\nin di\nng to\nT LR\n/M D 2 co m pl\nex E\nnd os\nom al\npH m\nod ul\nat io\nn\nIn hi\nbi tin g M yD 88\n-d ep\nen de nt N F -k B pa th w ay\nIn hi\nbi tin\ng LP\nS in\ndu ce d N F -k B si gn al in g\nIn hi\nbi tin\ng LP\nS in\ndu ce d N F -k B si gn al in g\nIn hi\nbi tin\ng bo\nth N\nF -k\nB an d IR F pa th w ay s\nR ef\ner en\nce s\nB ab\naz ad\na et\nal .,\n20 14\na, b\nF oi\nta nd\nT ha\nxt on\n,2 01\n6 P\ner ei\nra et\nal., 20\n12 R\nod rig\nue z\nLa va\ndo et\nal .,\n20 14\nYa ng\net al\n., 20\n15 ,2\n01 6\nN A\nH N\nP, no\nnan\ntic oa\ngu la\nnt he\npa rin\nna no\npa rt\nic le\n;H D\nL, hi\ngh -d\nen sity\nlip op\nro te\nin ;N\nP, na\nno pa\nrt ic\nle ;G\nN P,\ngo ld\nna no\npa rt\nic le\n;A po\nA 1,\nap ol\nip op\nro te\nin A\n1;N /A\n,n ot\nav ai\nla bl\ne.\nFrontiers in Physiology | www.frontiersin.org 13 July 2017 | Volume 8 | Article 508\nselecting di erent amino acids that are displayed on the GNPs. Thein vivoe cacy of P12 was investigated using a murine model of intestinal in ammation; it was found that P12 treatment could reduce the animal weight loss, improve the disease activity index, and ameliorate colonic in ammation.\nAll the above nanoparticles have minimum acute toxicity in culture cells as well as in the limited animal studies. However, since the gold nanoparticle is not biodegradable, the longterm safety issue of using GNP-based therapeutics is still a concern, even though they are well-tolerated in a phase I study. Therefore, addressing the long-term safety problem of GNPbased TLR inhibitors is critical in order to move this line of research into clinic uses. Alternatively, one could replace the GNP core with a biodegradable NP while maintaining the inhibitory activity, preferably targeting multiple TLRs like peptide-gold nanoparticle hybrids, to accelerate the translation of these novel agents into clinical treatments for in ammatory diseases.\nNote that the majority of these developed TLR nanoinhibitors act on TLR4 signaling, except the peptide-gold nanoparticle hybrid P12 which has shown inhibitory activity on multiple TLRs. In the current literatures reviewed, LPS has been used universally as the TLR4 agonist. However, other purinergic receptors, such as P2X7 receptor (encoded byP2RX7 gene), can also recognize LPS and induce the secretion of in ammatory mediators in macrophages (Denlinger et al., 2001). Interestingly, the recognition of LPS by P2X7 requires a coreceptor CD14, which facilitates LPS internalization and binding to the intracellular C-terminal domain of P2X7 (Dagvadorj et al., 2015). Therefore, the speci city of these nanoparticles in inhibition of TLR4 vs. other membrane receptors that also recognize LPS needs to be further addressed. It will also be interesting to see whether these nano-inhibitors can also modulate signaling of other TLRs in addition to TLR4.\nCurrently, these TLR nano-inhibitors are still at the preclinical investigation stage. Their pharmacokinetics and pharmacodynamics pro les in small and large animals need to be accomplished before launching any clinical trials. However, a few nanoparticles/nano-formulations have already been approved by FDA to deliver water-insoluble drugs or biologics, and have shown enhanced e cacy and safety pro les in cancer treatments. Some well-known examples include the polyethylene glycol (PEG) formulated L-asparaginase (Oncaspar by Sigma-Tau Pharmaceuticals, Inc.) and liposome formulated doxorubicin (Doxil by Jansen Pharmaceutical). Furthermore, several inorganic nanoparticles have been approved by FDA as diagnostic imaging agents. For instance, the iron oxide nanoparticles (Feridex by Bayer HealthCare Pharmaceuticals Inc.) have been used in medical magnetic resonance imaging (MRI). Recent records of clinically used nanoparticles are summarized in two comprehensive reviews in 2016 (Anselmo and Mitragotri, 2016; Bobo et al., 2016). Di erent from the clinically used nano-therapeutics, the reviewed TLR nanoinhibitors herein would represent a new class of nano-drug modulating TLR signaling, and hold great promise for clinical use in the future.\nCONCLUDING REMARKS\nTLRs are very important PRRs in the rst-line defense system of our bodies. They can recognize both invading pathogens and endogenous danger molecules released from dying cells and damaged tissues, and play a key role in linking innate and adaptive immunity. Despite their wellknown function in sensing pathogens and mounting defense mechanisms, overactivation of TLRs can ultimately lead to disruption of immune homeostasis, and thus increase the risk for in ammatory diseases and autoimmune disorders, such as SLE, RA, atherosclerosis, stoke, IR-induced injury, COPD, asthma, gastrointestinal in ammation, and even cancer. Evidences have shown the involvement of TLRs in the development and progression of these diseases. Accordingly, antagonists/inhibitors targeting TLR signaling pathways have emerged as novel therapeutics to treat these diseases. Although, this therapeutic strategy has been well-accepted experimentally, there are only limited numbers of TLR inhibitors/antagonists that have undergone clinical trials to date; many of them failed during the trials, and none have been approved for clinical uses. Lessons have been learned from these failed developments. The e cacy, safety, and stability of the new therapeutic agents, as well as whether these therapies could impair local immune defenses should be considered comprehensively in the clinical development. More importantly, given the facts that pathogen infection or danger signals often activate multiple TLRs, and that the failure of TLR4 speci c antagonist/inhibitor in the clinical trials despite its success in preclinical studies, developing more potent antagonists/inhibitors that target multiple TLR signaling pathways perhaps could shine the way to facilitate the translation of such a promising strategy into clinical uses in the future. Certainly, nano-devices will play an important role in the development of next generation TLR inhibitors.\nAUTHOR CONTRIBUTIONS\nQL and HY proposed and designed the scope of the review. WG and HY wrote the manuscript. YX and QL critically revised and commented on the manuscript. All the authors read and approved the nal manuscript and agreed to be accountable for the accuracy and integrity of any part of the manuscript.\nCKNOWLEDGMENTS\nQL would like to thank the support from the National Natural Science Foundation of China (Grant No. 81170060/H0111). HY would like to acknowledge the support from the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (TP2016014), the startingfund from Shanghai First People’s Hospital, Gaofeng Clinical Medicine Grant support from Shanghai Jiaotong University School of Medicine, and the funding from the Crohn’s and Colitis Foundation of Canada (CCFC).\nFrontiers in Physiology | www.frontiersin.org 14 July 2017 | Volume 8 | Article 508\nREFERENCES\nAkira, S., and Takeda, K. (2004). Toll-like receptor signalling.Nat Rev. Immunol. 4, 499 511. doi: 10.1038/nri1391 Anselmo, A., and Mitragotri, S. (2016). Nanoparticles in the clinic.B oeng. Transl. Med.1, 10 29. doi: 10.1002/btm2.10003 Arslan, F., Houtgraaf, J. H., Keogh, B., Kazemi, K., de Jong, R., McCormack, W. J., et al. (2012). Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs.Circ. Cardiovasc. Interv.5, 279 287. doi: 10.1161/CIRCINTERVENTIONS.111.967596 Babazada, H., Yamashita, F., and Hashida, M. (2014a). Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4-NF-kappaB signaling.J Control. Release194, 295 300. doi: 10.1016/j.jconrel.2014.09.015 Babazada, H., Yamashita, F., Yanamoto, S., and Hashida, M. (2014b). Selfassembling lipid modi ed glycol-split heparin nanoparticles suppress lipopolysaccharide-induced in ammation through TLR4-NF-kappaB signaling. J. Control. Release194, 332 340. doi: 10.1016/j.jconrel.2014. 09.011 Barochia, A., Solomon, S., Cui, X., Natanson, C., and Eichacker,P. Q. (2011). Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.Expert Opin. Drug Metab. Toxicol.7, 479 494. doi: 10.1517/17425255.2011.558190 Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C., and Co man, R. L. (2007). Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of diseasesymptoms. Eur. J. Immunol.37, 3582 3586. doi: 10.1002/eji.200737815 Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira S., et al. (2005). Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.J. Exp. Med.202, 1131 1139. doi: 10.1084/jem.20050914 Bartel, D. P. (2009). MicroRNAs: target recognition and regulatoryfunctions.Cell 136, 215 233. doi: 10.1016/j.cell.2009.01.002 Bergt, S., Wagner, N. M., Heidrich, M., Butschkau, A., Noldge-Schomburg, G. E., Vollmar, B., et al. (2013). Hydrocortisone reduces the bene cial e ects of tolllike receptor 2 de ciency on survival in a mouse model of polymicrobialsepsis. Shock40, 414 419. doi: 10.1097/SHK.0000000000000029 Beutler, B. A. (2009). TLRs and innate immunity.Blood 113, 1399 1407. doi: 10.1182/blood-2008-07-019307 Bezemer, G. F., Sagar, S., van Bergenhenegouwen, J., Georgiou, N. A., Garssen, J., Kraneveld, A. D., et al. (2012). Dual role of Toll-like receptors in asthma and chronic obstructive pulmonary disease.Pharmacol. Rev.64, 337 358. doi: 10.1124/pr.111.004622 Blanco, E., Shen, H., and Ferrari, M. (2015). Principles of nanoparticledesign for overcoming biological barriers to drug delivery.Nat. Biotechnol.33, 941 951. doi: 10.1038/nbt.3330 Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., and Corrie, S. R. (2016). Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date.Pharm. Res. 33, 2373 2387. doi: 10.1007/s11095-016-1958-5 Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L.,Kalwani, M., et al. (2011). miR-146a is a signi cant brake on autoimmunity, myeloproliferation, and cancer in mice.J. Exp. Med.208, 1189 1201. doi: 10.1084/jem.201 01823 Bom m, G. F., Echem, C., Martins, C. B., Costa, T. J., Sartoretto, S.M., Dos Santos, R. A., et al. (2015). Toll-like receptor 4 inhibition reduces vascular in ammation in spontaneously hypertensive rats.Life Sci.122, 1 7. doi: 10.1016/j.lfs.2014.12.001 Borges, M. C., Castro, L. A., and Fonseca, B. A. (2013). Chloroquine se improves dengue-related symptoms.Mem. Inst. Oswaldo Cruz108, 596 599. doi: 10.1590/S0074-02762013000500010 Botos, I., Segal, D. M., and Davies, D. R. (2011). The structuralbiology of Toll-like receptors.Structure19, 447 459. doi: 10.1016/j.str.2011.02.004 Brandenburg, K., Jurgens, G., Andra, J., Lindner, B., Koch, M.H., Blume, A., et al. (2002). Biophysical characterization of the interaction of highdensity lipoprotein (HDL) with endotoxins.Eur. J. Biochem.269, 5972 5981. doi: 10.1046/j.1432-1033.2002.03333.x\nBrea, D., Sobrino, T., Rodriguez-Yanez, M., Ramos-Cabrer, P., Agulla, J., Rodriguez-Gonzalez, R., et al. (2011). Toll-like receptors 7 and 8 expression is associated with poor outcome and greater in ammatory response in acute ischemic stroke.Clin. Immunol.139, 193 198. doi: 10.1016/j.clim.2011.02.001 Bryant, C. E., Symmons, M., and Gay, N. J. (2015). Toll-like receptor signalling through macromolecular protein complexes.Mol. Immunol. 63, 162 165. doi: 10.1016/j.molimm.2014.06.033 Buchanan, M. M., Hutchinson, M., Watkins, L. R., and Yin, H. (2010). Toll-like receptor 4 in CNS pathologies.J. Neurochem.114, 13 27. doi: 10.1111/j.1471-4159.2010.06736.x Capolunghi, F., Rosado, M. M., Cascioli, S., Girolami, E., Bordasco, S., Vivarelli, M., et al. (2010). Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients.Rheumatology 49, 2281 2289. doi: 10.1093/rheumatology/keq226 Cavassani, K. A., Ishii, M., Wen, H., Schaller, M. A., Lincoln, P.M., Lukacs, N. W., et al. (2008). TLR3 is an endogenous sensor of tissue necrosis during acute in ammatory events.J. Exp. Med.205, 2609 2621. doi: 10.1084/jem.200 81370 Celhar, T., and Fairhurst, A. M. (2014). Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment.Front. Pharmacol.5:265. doi: 10.3389/fphar.2014.00265 Ceppi, M., Pereira, P. M., Dunand-Sauthier, I., Barras, E., Reith,W., Santos, M. A., et al. (2009). MicroRNA-155 modulates the interleukin-1 signalingpathway in activated human monocyte-derived dendritic cells.Proc. Natl. Acad. Sci. U.S.A. 106, 2735 2740. doi: 10.1073/pnas.0811073106 Chames, P., Van Regenmortel, M., Weiss, E., and Baty, D. (2009). Therapeutic antibodies: successes, limitations and hopes for the future.Br. J. Pharmacol. 157, 220 233. doi: 10.1111/j.1476-5381.2009.00190.x Chen, M., Zhang, W., Xu, W., Zhang, F., and Xiong, S. (2011). Blockade of TLR9 signaling in B cells impaired anti-dsDNA antibody production in mice induced by activated syngenic lymphocyte-derived DNA immunization.Mol. Immunol. 48, 1532 1539. doi: 10.1016/j.molimm.2011.04.016 Christ, W. J., Asano, O., Robidoux, A. L., Perez, M., Wang, Y., Dubuc, G. R., et al. (1995). E5531, a pure endotoxin antagonist of high potency.S ience268, 80 83. doi: 10.1126/science.7701344 Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., and Shlomchik, M. J. (2006). Toll-like receptor 7 and TLR9 dictate autoantibody speci city and have opposing in ammatory and regulatory roles in a murine model of lupus.Immunity 25, 417 428. doi: 10.1016/j.immuni.2006. 07.013 Clancy, R. M., Markham, A. J., and Buyon, J. P. (2016). Endosomal Toll- ike receptors in clinically overt and silent autoimmunity.Immunol. Rev.269, 76 84. doi: 10.1111/imr.12383 Cui, G., Ye, X., Zuo, T., Zhao, H., Zhao, Q., Chen, W., et al. (2013). Chloroquine pretreatment inhibits toll-like receptor 3 signaling after stroke.Neurosci. Lett. 548, 101 104. doi: 10.1016/j.neulet.2013.02.072 Dagvadorj, J., Shimada, K., Chen, S., Jones, H. D., Tumurkhuu, G., Zhang, W., et al. (2015). Lipopolysaccharide induces Alveolar Macrophage Necrosis via CD14 and the P2X7 receptor leading to interleukin-1a release.Immunity42, 640 653. doi: 10.1016/j.immuni.2015.03.007 Dasu, M. R., Riosvelasco, A. C., and Jialal, I. (2009). Candesartan inhibits Toll-like receptor expression and activity bothin vitro and in vivo. Atherosclerosis202, 76 83. doi: 10.1016/j.atherosclerosis.2008.04.010 Daubeuf, B., Mathison, J., Spiller, S., Hugues, S., Herren, S., Ferlin, W., et al. (2007). TLR4/MD-2 monoclonal antibody therapy a ords protection in experimental models of septic shock.J Immunol. 179, 6107 6114. doi: 10.4049/jimmunol.179.9.6107 Denlinger, L. C., Fisette, P. L., Sommer, J. A., Watters, J. J., Prabhu, U., Dubyak, G. R., et al. (2001). Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide.J. Immunol.167, 1871 1876. doi: 10.4049/jimmunol.167.4.1871 Dong, L., Li, H., Wang, S., and Li, Y. (2009). Di erent doses of lipopolysaccharides regulate the lung in ammation of asthmatic mice via TLR4 pathway in alveo ar macrophages.J. Asthma46, 229 233. doi: 10.1080/02770900802610050 Drexler, S. K., and Foxwell, B. M. (2010). The role of toll-like receptors in chronic in ammation. Int. J. Biochem. Cell Biol.42, 506 518. doi: 10.1016/j.biocel.2009.10.009\nFrontiers in Physiology | www.frontiersin.org 15 July 2017 | Volume 8 | Article 508\nDroemann, D., Goldmann, T., Tiedje, T., Zabel, P., Dalho , K., and Schaaf, B. (2005). Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients.Respir. Res.6:68. doi: 10.1186/1465-9921-6-68 Dynavax (2014).Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Collaboration with GSK. Available online at: http://investors.dynavax.com/releasedetail.cfm?releaseid=885172 (Accessed November 28, 2014). Edfeldt, K., Swedenborg, J., Hansson, G. K., and Yan, Z. Q. (2002). Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation.Circulation 105, 1158 1161. doi: 10.1161/01.CIR. 0000012489.17433.31 Ehrentraut, H., Weber, C., Ehrentraut, S., Schwederski, M., Boehm, O., Knuefermann, P., et al. (2011). The toll-like receptor 4-antagonisteritoran reduces murine cardiac hypertrophy.Eur. J. Heart Fail.13, 602 610. doi: 10.1093/eurjhf/hfr035 Ernsting, M. J., Murakami, M., Roy, A., and Li, S. D. (2013). Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Release172, 782 794. doi: 10.1016/j.jconrel.2013.09.013 Fang, D., Yang, S., Quan, W., Jia, H., Quan, Z., and Qu, Z. (2014). Atorvastatin suppresses toll-like receptor 4 expression and NF-kB activation in rabbit atherosclerotic plaques.Eur. Rev. Med. Pharmacol. Sci.18, 242 246. Farrar, C. A., Keogh, B., McCormack, W., O’Shaughnessy, A., Parker, A., Reilly, M., et al. (2012). Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury.FASEB J.26, 799 807. doi: 10.1096/fj.11-195396 Foit, L., and Thaxton, C. S. (2016). Synthetic high-densitylipoprotein-like nanoparticles potently inhibit cell signaling and production of in ammatory mediators induced by lipopolysaccharide binding Toll-like receptor 4. Biomaterials100, 67 75. doi: 10.1016/j.biomaterials.2016.05.021 Foldes, G., von Haehling, S., Okonko, D. O., Jankowska, E. A., Poole-Wilson, P. A., and Anker, S. D. (2008). Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int. J. Cardiol.124, 80 85. doi: 10.1016/j.ijcard.2006.12.024 Fox, R. (1996). Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.Lupus 5(Suppl. 1), S4 S10. doi: 10.1177/096120339600500103 Fukata, M., and Abreu, M. T. (2008). Role of Toll-like receptors in gastrointestinal malignancies.Oncogene27, 234 243. doi: 10.1038/sj.onc.1210908 Fukata, M., Chen, A., Vamadevan, A. S., Cohen, J., Breglio, K., Krishnareddy, S., et al. (2007). Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.Gastroenterology133, 1869 1881. doi: 10.1053/j.gastro.2007.09.008 Gay, N. J., Symmons, M. F., Ganglo , M., and Bryant, C. E. (2014). Assembly and localization of Toll-like receptor signalling complexes.Nat. Rev. Immunol.14, 546 558. doi: 10.1038/nri3713 Gesuete, R., Kohama, S. G., and Stenzel-Poore, M. P. (2014). Toll-like receptors and ischemic brain injury.J. Neuropathol. Exp. Neurol.73, 378 386. doi: 10.1097/NEN.0000000000000068 Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thurlimann, W., Burg, G., et al. (2004). Psoriasis triggered by toll-like receptor 7 agonist imiquimodin the presence of dermal plasmacytoid dendritic cell precursors.Arch. Dermatol.140, 1490 1495. doi: 10.1001/archderm.140.12.1490 Gomez-Guzman, M., Jimenez, R., Romero, M., Sanchez, M., Zarzuelo, M. J., Gomez-Morales, M., et al. (2014). Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus.Hypertension 64, 330 337. doi: 10.1161/HYPERTENSIONAHA.114.03587 Goulopoulou, S., McCarthy, C. G., and Webb, R. C. (2016). Toll-like rec ptors in the vascular system: sensing the dangers within.Pharmacol. Rev.68, 142 167. doi: 10.1124/pr.114.010090 Guiducci, C., Gong, M., Xu, Z., Gill, M., Chaussabel, D., Meeker,T., et al. (2010). TLR recognition of self nucleic acids hampers glucocorticoid activity n lupus. Nature465, 937 941. doi: 10.1038/nature09102 Guo, L., Ai, J., Zheng, Z., Howatt, D. A., Daugherty, A., Huang, B., et al. (2013). High density lipoprotein protects against polymicrobe-induced sepsis in mice. J. Biol. Chem.288, 17947 17953. doi: 10.1074/jbc.M112.442699 Harter, L., Mica, L., Stocker, R., Trentz, O., and Keel, M. (2004). Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock22, 403 409. doi: 10.1097/01.shk.0000142256.23382.5d Hatterer, E., Shang, L., Simonet, P., Herren, S., Daubeuf, B., Teixeira, S., et al. (2016). A speci c anti-citrullinated protein antibody pro le identi es a group of rheumatoid arthritis patients with a toll-like receptor 4-mediateddisease. Arthritis Res. Ther.18, 224. doi: 10.1186/s13075-016-1128-5 He, C., Hu, Y., Yin, L., Tang, C., and Yin, C. (2010). E ects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles.Biomaterials 31, 3657 3666. doi: 10.1016/j.biomaterials.2010.01.065 He, X., Jing, Z., and Cheng, G. (2014). MicroRNAs: new regulators of Toll-like receptor signalling pathways.Biomed Res. Int.2014:945169. doi: 10.1155/2014/945169 Hedayat, M., Netea, M. G., and Rezaei, N. (2011). Targeting ofToll-like receptors: a decade of progress in combating infectious diseases.Lancet Infect. Dis.11, 702 712. doi: 10.1016/S1473-3099(11)70099-8 Hennessy, E. J., Parker, A. E., and O’Neill, L. A. (2010). Targeting Tolllike receptors: emerging therapeutics?Nat. Rev. Drug Discov.9, 293 307. doi: 10.1038/nrd3203 Hernanz, R., Martinez-Revelles, S., Palacios, R., Martin, A., Cachofeiro, V., Aguado, A., et al. (2015). Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br. J. Pharmacol.172, 3159 3176. doi: 10.1111/bph. 13117 Higashimori, M., Tatro, J. B., Moore, K. J., Mendelsohn, M. E., Galper, J. B., and Beasley, D. (2011). Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-de cient mice.Arterioscler. Thromb. Vasc. Biol.31, 50 57. doi: 10.1161/ATVBAHA.110.210971 Hou, L. F., He, S. J., Li, X., Yang, Y., He, P. L., Zhou, Y., et al. (2011). Oral administration of artemisinin analog SM934 ameliorates lupus syndromesin MRL/lpr mice by inhibiting Th1 and Th17 cell responses.Arthritis Rheum.63, 2445 2455. doi: 10.1002/art.30392 Houghton, J., and Wang, T. C. (2005). Helicobacter pylori and gastric cancer: a new paradigm for in ammation-associated epithelial cancers.Gastroenterology 128, 1567 1578. doi: 10.1053/j.gastro.2005.03.037 Hu, D., Yang, X., Xiang, Y., Li, H., Yan, H., Zhou, J., et al. (2015). Inhibition of Toll-like receptor 9 attenuates sepsis-induced mortality through suppressing excessive in ammatory response.C ll. Immunol.295, 92 98. doi: 10.1016/j.cellimm.2015.03.009 Ishibashi, M., Sayers, S., D’Armiento, J. M., Tall, A. R., and Welch, C. L. (2013). TLR3 de ciency protects against collagen degradation and medial destruction in murine atherosclerotic plaques.Atherosclerosis229, 52 61. doi: 10.1016/j.atherosclerosis.2013.03.035 Itzkowitz, S. H., and Yio, X. (2004). In ammation and cancer IV. Colorectal cancer in in ammatory bowel disease: the role of in ammation.Am. J. Physiol. Gastrointest. Liver Physiol.287, G7 17. doi: 10.1152/ajpgi.00079.2004 Jackson, S. W., Scharping, N. E., Kolhatkar, N. S., Khim, S., Schwartz, M. A., Li, Q. Z., et al. (2014). Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic in ammation.J. Immunol.192, 4525 4532. doi: 10.4049/jimmunol.1400098 Jiang, W., Zhu, F., Tang, J., Kandimalla, E., La Monica, N., and Agrawal, S. (2012). IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhib ts disease development in mouse models of psoriasis.J. Immunol.188 (1 Suppl.), 119.8. Karimi, K., Sarir, H., Mortaz, E., Smit, J. J., Hosseini, H., De Kimpe, S. J., et al. (2006). Toll-like receptor-4 mediates cigarette smokeinduced cytokine production by human macrophages.Respir. Res.7:66. doi: 10.1186/1465-9921-7-66 Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.Nat. Immunol.11, 373 384. doi: 10.1038/ni.1863 Kawasaki, T., and Kawai, T. (2014). Toll-like receptor signaling pathw ys.Front. Immunol.5:461. doi: 10.3389/ mmu.2014.00461 Khan, A. M., Li, M., Abdulnour-Nakhoul, S., Maderdrut, J. L., Simon, E. E., and Batuman, V. (2012). Delayed administration of pituitary adenylate cyclase-activating polypeptide 38 ameliorates renal ischemia/reperfusion injury in mice by modulating Toll-like receptors.Peptides38, 395 403. doi: 10.1016/j.peptides.2012.09.023\nFrontiers in Physiology | www.frontiersin.org 16 July 2017 | Volume 8 | Article 508\nKim, W. U., Yoo, S. A., Min, S. Y., Park, S. H., Koh, H. S., Song, S. W., et al. (2006). Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes.Clin. Exp. Immunol.144, 503 511. doi: 10.1111/j.1365-2249.2006.03070.x Komatsuda, A., Wakui, H., Iwamoto, K., Ozawa, M., Togashi, M., Masai, R., et al. (2008). Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin. Exp. Immunol.152, 482 487. doi: 10.1111/j.1365-2249.2008.03646.x Kono, D. H., Haraldsson, M. K., Lawson, B. R., Pollard, K. M., Koh, Y.T., Du, X., et al. (2009). Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus.Proc. Natl. Acad. Sci. U.S.A.106, 12061 12066. doi: 10.1073/pnas.0905441106 Koulis, C., Chen, Y. C., Hausding, C., Ahrens, I., Kyaw, T. S., Tay, C., et al. (2014). Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-de cient mice.Arterioscler. Thromb. Vasc. Biol.34, 516 525. doi: 10.1161/ATVBAHA.113.302407 Kuznik, A., Bencina, M., Svajger, U., Jeras, M., Rozman, B., and Jerala, R. (2011). Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.J. Immunol. 186, 4794 4804. doi: 10.4049/jimmunol.1000702 Lartigue, A., Colliou, N., Calbo, S., Francois, A., Jacquot, S., Arnoult, C., et al. (2009). Critical role of TLR2 and TLR4 in autoantibody productiona d glomerulonephritis in lpr mutation-induced mouse lupus.J Immunol.183, 6207 6216. doi: 10.4049/jimmunol.0803219 Lee, P. Y., Kumagai, Y., Li, Y., Takeuchi, O., Yoshida, H., Weinst i , J., et al. (2008). TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.J. Exp. Med.205, 2995 3006. doi: 10.1084/jem.20080462 Lee, S. J., Silverman, E., and Bargman, J. M. (2011). The role of antimalarial agents in the treatment of SLE and lupus nephritis.Nat. Rev. Nephrol.7, 718 729. doi: 10.1038/nrneph.2011.150 Lee, Y. H., Choi, S. J., Ji, J. D., and Song, G. G. (2016). Association between toll-like receptor polymorphisms and systemic lupus erythematosus: a meta-analysis update.Lupus25, 593 601. doi: 10.1177/0961203315622823 Lesiak, A., Narbutt, J., Sysa-Jedrzejowska, A., Lukamowicz,J., McCauli e, D. P., and Wozniacka, A. (2010). E ect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus19, 683 688. doi: 10.1177/0961203309356455 Leung, P. Y., Stevens, S. L., Packard, A. E., Lessov, N. S., Yang T., Conrad, V. K., et al. (2012). Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferonmediated mechanism.Stroke43, 1383 1389. doi: 10.1161/STROKEAHA.111. 641522 Li, N., Harkema, J. R., Lewandowski, R. P., Wang, M., Bramble, L. A., Gookin, G. R., et al. (2010). Ambient ultra ne particles provide a strong adjuvant e ect in the secondary immune response: implication for tra crelated asthma ares.Am. J. Physiol. Lung Cell. Mol. Physiol.299, L374 383. doi: 10.1152/ajplung.00115.2010 Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R. Jr., Gannon, W. E., Walker, M., et al. (2010). Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.Clin. Cancer Res.16, 6139 6149. doi: 10.1158/1078-0432.CCR-10-0978 Lima, C. X., Souza, D. G., Amaral, F. A., Fagundes, C. T., Rodrigues,I. P., Alves-Filho, J. C., et al. (2015). Therapeutic e ects of treatment with antiTLR2 and anti-TLR4 monoclonal antibodies in polymicrobial sepsis.PLoS ONE 10:e0132336. doi: 10.1371/journal.pone.0132336 Lin, P. J., and Tam, Y. K. (2015). Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems.Future Med. Chem.7, 1751 1769. doi: 10.4155/fmc.15.108 Lipford, G., Forsbach, A., Zepp, C., Nguyen, T., Weeratna, R., McCluskie, M., et al. (2007). Selective toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases, inAmerican College of Rheumatology 2007 Annual Scienti c Meeting(Boston, MA). Liu, B., Yang, Y., Dai, J., Medzhitov, R., Freudenberg, M. A.,Zhang, P. L., et al. (2006). TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease.J. Immunol.177, 6880 6888. doi: 10.4049/jimmunol.177.10.6880 Liu, L., Li, Y., Hu, Z., Su, J., Huo, Y., Tan, B., et al. (2012). Smallinterfering RNA targeting Toll-like receptor 9 protects mice against polymicrobial septic acute kidney injury.Nephron Exp. Nephrol.122, 51 61. doi: 10.1159/000346953 Liu, M., Gu, M., Xu, D., Lv, Q., Zhang, W., and Wu, Y. (2010). Protective e ects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant. Proc.42, 1539 1544. doi: 10.1016/j.transproceed.2010. 03.133 Lo er, B. M., Bohn, E., Hesse, B., and Kunze, H. (1985). E ects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver.Biochim. Biophys. Acta835, 448 455. doi: 10.1016/0005-2760(85)90114-6 Loiarro, M., Capolunghi, F., Fanto, N., Gallo, G., Campo, S., Arseni,B., et al. (2007). Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.J. Leukoc. Biol.82, 801 810. doi: 10.1189/jlb.1206746 Lyn-Cook, B. D., Xie, C., Oates, J., Treadwell, E., Word, B., Hammons, G., et al. (2014). Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnicdi erences and potential new targets for therapeutic drugs.Mol. Immunol. 61, 38 43. doi: 10.1016/j.molimm.2014.05.001 Lynn, M., Wong, Y. N., Wheeler, J. L., Kao, R. J., Perdomo, C. A., Noveck, R., et al. (2004). Extendedin vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].J. Pharmacol. Exp. Ther.308, 175 181. doi: 10.1124/jpet.103.056531 Marshak-Rothstein, A. (2006). Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol.6, 823 835. doi: 10.1038/nri1957 Matsunaga, N., Tsuchimori, N., Matsumoto, T., and Ii, M. (2011). TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions betwe n TLR4 and its adaptor molecules.Mol. Pharmacol.79, 34 41. doi: 10.1124/mol.110. 068064 McCarthy, C. G., Goulopoulou, S., Wenceslau, C. F., Spitler, K., Matsumoto, T., and Webb, R. C. (2014). Toll-like receptors and damage-associated molecular patterns: novel links between in ammation and hypertension. Am. J. Physiol. Heart Circ. Physiol.306, H184 H196. doi: 10.1152/ajpheart.0032 8.2013 McCarthy, C. G., Wenceslau, C. F., Goulopoulou, S., Ogbi, S., Baban, B., Sullivan, J. C., et al. (2015). Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc. Res.107, 119 130. doi: 10.1093/cvr/cvv137 Meng, G., Rutz, M., Schiemann, M., Metzger, J., Grabiec, A., Schwandner, R., et al. (2004). Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes.J Clin. Invest.113, 1473 1481. doi: 10.1172/JCI 20762 Methe, H., Kim, J. O., Ko er, S., Nabauer, M., and Weis, M. (2005). Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14C monocytes.Arterioscler. Thromb. Vasc. Biol.25, 1439 1445. doi: 10.1161/01.ATV.0000168410.44722.86 Michelsen, K. S., Wong, M. H., Shah, P. K., Zhang, W., Yano, J., Doherty, T. M., et al. (2004). Lack of Toll-like receptor 4 or myeloid di erentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice de cient in apolipoprotein E.Proc. Natl. Acad. Sci. U.S.A.101, 10679 10684. doi: 10.1073/pnas.0403249101 Miller, L. S., Sorensen, O. E., Liu, P. T., Jalian, H. R., Eshtiaghpour, D., Behmanesh, B. E., et al. (2005). TGF-alpha regulates TLR expression and function on epidermal keratinocytes.J. Immunol. 174, 6137 6143. doi: 10.4049/jimmunol.174.10.6137 Miller, Y. I. (2005). Toll-like receptors and atherosclerosis: oxidize LDL as an endogenous Toll-like receptor ligand.Future Cardiol.1, 785 792. doi: 10.2217/14796678.1.6.785 Mogensen, T. H. (2009). Pathogen recognition and in ammatory signaling in innate immune defenses.Clin. Microbiol. Rev. 22, 240 273. doi: 10.1128/CMR.00046-08 Monaco, C., Gregan, S. M., Navin, T. J., Foxwell, B. M., Davies, A. H., and Feldmann, M. (2009). Toll-like receptor-2 mediates in ammation and matrix degradation in human atherosclerosis.Circulation 120, 2462 2469. doi: 10.1161/CIRCULATIONAHA.109.851881\nFrontiers in Physiology | www.frontiersin.org 17 July 2017 | Volume 8 | Article 508\nMonnet, E., Lapeyre, G., Poelgeest, E. V., Jacqmin, P., Graaf, K.,Reijers, J., et al. (2017). Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteersr ceiving LPS.Clin. Pharmacol. Ther.101, 200 208. doi: 10.1002/cpt.522 Monnet, E., Shang, L., Lapeyre, G., deGraaf, K., Hatterer, E., Buatois, V., et al. (2015). NI-0101, a monoclonal antibody targeting tolllike receptor 4 (TLR4) being developed for rheumatoid arthritis (RA) treatment with a potential for personalized medicineAnn. Rheum. Dis.74, 1. doi: 10.1136/annrheumdis-2015-eular.3801 Moresco, E. M., LaVine, D., and Beutler, B. (2011). Toll-like receptors.Curr. Biol. 21, R488 R493. doi: 10.1016/j.cub.2011.05.039 Mortaz, E., Adcock, I. M., Ito, K., Kraneveld, A. D., Nijkamp, F. P., and Folkerts, G. (2010). Cigarette smoke induces CXCL8 production by human neutrophils via activation of TLR9 receptor.Eur. Respir. J.36, 1143 1154. doi: 10.1183/09031936.00062209 Mullarkey, M., Rose, J. R., Bristol, J., Kawata, T., Kimura, A., Kobayashi, S., et al. (2003). Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.J. Pharmacol. Exp. Ther.304, 1093 1102. doi: 10.1124/jpet.102.044487 Mullick, A. E., Soldau, K., Kiosses, W. B., Bell, T. A. III., Tobias, P. S., and Curtiss, L. K. (2008). Increased endothelial expression of Toll-like receptor2 at sites of disturbed blood ow exacerbates early atherogenic events.J. Exp. Med.205, 373 383. doi: 10.1084/jem.20071096 Mullick, A. E., Tobias, P. S., and Curtiss, L. K. (2005). Modulation of atherosclerosis in mice by Toll-like receptor 2.J. Clin. Invest.115, 3149 3156. doi: 10.1172/JCI25482 Nickerson, K. M., Christensen, S. R., Shupe, J., Kashgarian, M., Kim, D., Elkon, K., et al. (2010). TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus.J. Immunol. 184, 1840 1848. doi: 10.4049/jimmunol.0902592 O’Connell, R. M., Kahn, D., Gibson, W. S., Round, J. L., Scholz, R. L., Chaudhuri, A. A., et al. (2010). MicroRNA-155 promotes autoimmune in ammation by enhancing in ammatory T cell development.Immunity 33, 607 619. doi: 10.1016/j.immuni.2010.09.009 O’Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G., and Baltimore, D. (2007). MicroRNA-155 is induced during the macrophage in ammatory response.Proc. Natl. Acad. Sci. U.S.A.104, 1604 1609. doi: 10.1073/pnas.0610731104 O’Neill, L. A., Bryant, C. E., and Doyle, S. L. (2009). Therapeutic targeting of Tolllike receptors for infectious and in ammatory diseases and cancer.Pharmacol. Rev.61, 177 197. doi: 10.1124/pr.109.001073 Opal, S. M., Laterre, P. F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J. P., et al. (2013). E ect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.JAMA 309, 1154 1162. doi: 10.1001/jama.2013.2194 Pajkrt, D., Doran, J. E., Koster, F., Lerch, P. G., Arnet, B., vander Poll, T., et al. (1996). Antiin ammatory e ects of reconstituted high-density lipoprotein during human endotoxemia.J. Exp. Med.184, 1601 1608. doi: 10.1084/jem.184.5.1601 Palm, N. W., and Medzhitov, R. (2009). Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227, 221 233. doi: 10.1111/j.1600-065X.2008.00731.x Pan, Y., Jia, T., Zhang, Y., Zhang, K., Zhang, R., Li, J., et al.(2012). MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice.Int. J. Nanomed.7, 5957 5967. doi: 10.2147/IJN.S37990 Park, B. S., Song, D. H., Kim, H. M., Choi, B. S., Lee, H., and Lee, J. O. (2009). The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature458, 1191 1195. doi: 10.1038/nature07830 Paton, N. I., Lee, L., Xu, Y., Ooi, E. E., Cheung, Y. B., Archuleta, S., et al. (2011). Chloroquine for in uenza prevention: a randomised, double-blind, placebo controlled trial.Lancet Infect. Dis.11, 677 683. doi: 10.1016/S1473-3099(11)70065-2 Pedrosa, P., Vinhas, R., Fernandes, A., and Baptista, P. V. (2015). Gold nanotheranostics: proof-of-concept or clinical tool?Nanomaterials 5, 1853 1879. doi: 10.3390/nano5041853 Pereira, D. V., Petronilho, F., Pereira, H. R., Vuolo, F., Mina, F., Possat , J. C., et al. (2012). E ects of gold nanoparticles on endotoxin-induceduveitis in rats. Invest. Ophthalmol. Vis. Sci.53, 8036 8041. doi: 10.1167/iovs.12-10743 Pisitkun, P., Deane, J. A., Di lippantonio, M. J., Tarasenko, T., Satterthwaite, A. B., and Bolland, S. (2006). Autoreactive B cell responses to RNArelated antigens due to TLR7 gene duplication.Science312, 1669 1672. doi: 10.1126/science.1124978 Quinn, S. R., and O’Neill, L. A. (2011). A trio of microRNAs that contr l Tolllike receptor signalling.Int. Immunol. 23, 421 425. doi: 10.1093/intimm/ dxr034 Reilly, M., Miller, R. M., Thomson, M. H., Patris, V., Ryle, P., McLoughlin, L., et al. (2013). Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.Clin. Pharmacol. Ther.94, 593 600. doi: 10.1038/clpt.2013.150 Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J. L., Angus, D. C., Aikawa, N., et al. (2010). A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.Crit. Care Med.38, 1685 1694. doi: 10.1097/CCM.0b013e3181e7c5c9 Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., et al. (1994). Bacterial endotoxin: molecular relationships of structu e to activity and function.FASEB J.8, 217 225. Rodrigues, F. L., Silva, L. E., Hott, S. C., Bom m, G. F., da Silva, C.A., Fazan, R. Jr., et al. (2015). Toll-like receptor 9 plays a key role in the autonomic cardiac and barore ex control of arterial pressure.Am. J. Physiol. Regul. Integr. Comp. Physiol.308, R714 R723. doi: 10.1152/ajpregu.00150.2014 Rodriguez Lavado, J., Sestito, S. E., Cighetti, R., Aguilar Moncayo, E. M., Oblak, A., Lainscek, D., et al. (2014). Trehalose- and glucose-derived glycoamphiphiles: small-molecule and nanoparticle Toll-like receptor 4 (TLR4) modulators.J. Med. Chem.57, 9105 9123. doi: 10.1021/jm501182w Roger, T., Froidevaux, C., Le Roy, D., Reymond, M. K., Chanson,A. L., Mauri, D., et al. (2009). Protection from lethal gram-negative bacterial sepsi by targeting Toll-like receptor 4.Proc. Natl. Acad. Sci. U.S.A.106, 2348 2352. doi: 10.1073/pnas.0808146106 Rommler, F., Hammel, M., Waldhuber, A., Muller, T., Jurk, M., Uhlmann, E.,et al. (2015). Guanine-modi ed inhibitory oligonucleotides e ciently impair TLR7and TLR9-mediated immune responses of human immune cells.PLoS ONE 10:e0116703. doi: 10.1371/journal.pone.0116703 Rommler, F., Jurk, M., Uhlmann, E., Hammel, M., Waldhuber, A., Pfei er, L., et al. (2013). Guanine modi cation of inhibitory oligonucleotides potentiates their suppressive function.J. Immunol. 191, 3240 3253. doi: 10.4049/jimmunol.1300706 Rossignol, D. P., Wasan, K. M., Choo, E., Yau, E., Wong, N., Rose, J., et al. (2004). Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenousinfusion into healthy volunteers.Antimicrob. Agents Chemother.48, 3233 3240. doi: 10.1128/AAC.48.9.3233-3240.2004 Rossignol, D. P., Wong, N., Noveck, R., and Lynn, M. (2008). Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.Innate Immun.14, 383 394. doi: 10.1177/1753425908099173 Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., and Khamashta, M. A. (2010). Clinical e cacy and side e ects of antimalarials in systemic lupus erythematosus: a systematic review.Ann. Rheum. Dis.69, 20 28. doi: 10.1136/ard.2008.101766 Sato, S., Sugiyama, M., Yamamoto, M., Watanabe, Y., Kawai, T., Takeda, K., et al. (2003). Toll/IL-1 receptor domain-containing adaptor inducing IFN-b (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kB and IFN-regulatory factor-3, in the toll-like receptor signaling.J. Immunol. 171, 4304 4310. doi: 10.4049/jimmunol.171.8.4304 Sato, Y., Goto, Y., Narita, N., and Hoon, D. S. (2009). Cancer cells expressing tolllike receptors and the tumor microenvironment.Cancer Microenviron.2(Suppl. 1), 205 214. doi: 10.1007/s12307-009-0022-y Savov, J. D., Brass, D. M., Lawson, B. L., McElvania-Tekippe, E.,Walker, J. K., and Schwartz, D. A. (2005). Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.Am. J. Physiol. Lung Cell. Mol. Physiol.289, L329 L337. doi: 10.1152/ajplung.00014.2005 Seung, N. R., Park, E. J., Kim, C. W., Kim, K. H., Kim, K. J., Cho, H. J.,et al. (2007). Comparison of expression of heat-shock protein 60, Toll-like receptors 2and 4, and T-cell receptor gammadelta in plaque and guttate psoriasis.J. Cutan. Pathol.34, 903 911. doi: 10.1111/j.1600-0560.2007.00756.x\nFrontiers in Physiology | www.frontiersin.org 18 July 2017 | Volume 8 | Article 508\nSheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O’Leary, J. J., Ruan, Q., et al. (2010). Negative regulation of TLR4 via targeting of the proin ammatory tumor suppressor PDCD4 by the microRNA miR-21.Nat. Immunol.11, 141 147. doi: 10.1038/ni.1828 Shen, N., Liang, D., Tang, Y., de Vries, N., and Tak, P. P. (2012). MicroRNAs novel regulators of ystemic lupus erythematosus pathogenesis.Nat. Rev. Rheumatol. 8, 701 709. doi: 10.1038/nrrheum.2012.142 Shimamoto, A., Chong, A. J., Yada, M., Shomura, S., Takayama, H., Fleisig, A. J., et al. (2006). Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.Circulation114, I270 274. doi: 10.1161/CIRCULATIONAHA.105.000901 Shirey, K. A., Lai, W., Scott, A. J., Lipsky, M., Mistry, P., Pletneva, L. M., et al. (2013). The TLR4 antagonist Eritoran protects mice from lethal in uenza infection.Nature497, 498 502. doi: 10.1038/nature12118 Spiller, S., Elson, G., Ferstl, R., Dreher, S., Mueller, T., Freudenberg, M., et al. (2008). TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice.J. Exp. Med.205, 1747 1754. doi: 10.1084/jem.20071990 Stowell, N. C., Seideman, J., Raymond, H. A., Smalley, K. A., Lamb, R. J. Egenolf, D. D., et al. (2009). Long-term activation of TLR3 by poly(I:C) induces in ammation and impairs lung function in mice.Respir. Res.10:43. doi: 10.1186/1465-9921-10-43 Suarez-Farinas, M., Arbeit, R., Jiang, W., Ortenzio, F. S., Sullivan, T., and Krueger, J. G. (2013). Suppression of molecular in ammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skinin ammation. PLoS ONE8:e84634. doi: 10.1371/journal.pone.0084634 Subramanian, S., Tus, K., Li, Q. Z., Wang, A., Tian, X. H., Zhou, J., et al. (2006). A Tlr7 translocation accelerates systemic autoimmunity in murine lupus.Proc. Natl. Acad. Sci. U.S.A.103, 9970 9975. doi: 10.1073/pnas.0603912103 Suzuki, M., Kato, C., and Kato, A. (2015). Therapeutic antibodies: their mechanisms of action and the pathological ndings they induce intoxicity studies.J. Toxicol. Pathol.28, 133 139. doi: 10.1293/tox.2015-0031 Taganov, K. D., Boldin, M. P., Chang, K. J., and Baltimore, D. (2006). NFkappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.Proc. Natl. Acad. Sci. U.S.A. 103, 12481 12486. doi: 10.1073/pnas.0605298103 Takeda, K., and Akira, S. (2005). Toll-like receptors in innate immunity. Int. Immunol.17, 1 14. doi: 10.1093/intimm/dxh186 Takeda, K., Kaisho, T., and Akira, S. (2003). Toll-like receptors.Annu. Rev. Immunol. 21, 335 376. doi: 10.1146/annurev.immunol.21.120601. 141126 Tang, Y., Luo, X., Cui, H., Ni, X., Yuan, M., Guo, Y., et al. (2009).MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins.Arthritis Rheum.60, 1065 1075. doi: 10.1002/art.24436 Tidswell, M., Tillis, W., Larosa, S. P., Lynn, M., Wittek, A. E., Kao, R., et al. (2010). Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.Crit. Care Med.38, 72 83. doi: 10.1097/CCM.0b013e3181b07b78 Tili, E., Michaille, J. J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., et al. (2007). Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock.J. Immunol.179, 5082 5089. doi: 10.4049/jimmunol.179.8.5082 Tokairin, Y., Shibata, Y., Sata, M., Abe, S., Takabatake, N.,Igarashi, A., et al. (2008). Enhanced immediate in ammatory response toStreptococcus pneumoniaen the lungs of mice with pulmonary emphysema.Respirology13, 324 332. doi: 10.1111/j.1440-1843.2007.01229.x Tsujimoto, H., Ono, S., Efron, P. A., Scumpia, P. O., Moldawer, L. L., and Mochizuki, H. (2008). Role of Toll-like receptors in the development ofsepsis. Shock29, 315 321. doi: 10.1097/SHK.0b013e318157ee55 Tyrrell, D. J., Horne, A. P., Holme, K. R., Preuss, J. M., and Page, C. P. (1999). Heparin in in ammation: potential therapeutic applications beyond anticoagulation.Adv. Pharmacol.46, 151 208. doi: 10.1016/S1054-3589(08) 60471-8 Uematsu, S., and Akira, S. (2007). Toll-like receptors and Type I interferons.J. Biol. Chem.282, 15319 15323. doi: 10.1074/jbc.R700009200 Ultaigh, S. N., Saber, T. P., McCormick, J., Connolly, M., Dellacasagr nde, J., Keogh, B., et al. (2011). Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritisex vivosynovial explant cultures. Arthritis Res. Ther.13, R33. doi: 10.1186/ar3261 Ungaro, R., Fukata, M., Hsu, D., Hernandez, Y., Breglio, K., Chen, A., et al. (2009). A novel Toll-like receptor 4 antagonist antibody ameliorates in ammation but impairs mucosal healing in murine colitis.Am. J. Physiol. Gastrointest. Liver Physiol.296, G1167 1179. doi: 10.1152/ajpgi.90496.2008 Wang, L., Brown, J. R., Varki, A., and Esko, J. D. (2002). Heparin’s anti-in ammatory e ects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.J. Clin. Invest.110, 127 136. doi: 10.1172/JCI0214996 Wang, L., Li, Y. L., Zhang, C. C., Cui, W., Wang, X., Xia, Y., et al.(2014). Inhibition of Toll-like receptor 2 reduces cardiac brosis by attenuating macrophagemediated in ammation.Cardiovasc. Res.101, 383 392. doi: 10.1093/cvr/cvt258 Wang, Y. C., Lin, S., and Yang, Q. W. (2011). Toll-like receptors in cerebral ischemic in ammatory injury. J. Neuroin ammation 8:134. doi: 10.1186/1742-2094-8-134 Weber, S. M., Chen, J. M., and Levitz, S. M. (2002). Inhibition of mitogenactivated protein kinase signaling by chloroquine.J. Immunol.168, 5303 5309. doi: 10.4049/jimmunol.168.10.5303 Wittebole, X., Coyle, S. M., Kumar, A., Goshima, M., Lowry, S. F., and Calvano, S. E. (2005). Expression of tumour necrosis factor receptor and Toll-like receptor 2 and 4 on peripheral blood leucocytes of human volunteers after endotoxin challenge: a comparison of ow cytometric light scatter and immuno uorescence gating.Clin. Exp. Immunol.141, 99 106. doi: 10.1111/j.1365-2249.2005.02831.x Wozniacka, A., Lesiak, A., Boncela, J., Smolarczyk, K., McCauli e, D. P., and Sysa-Jedrzejowska, A. (2008). The in uence of antimalarialtre tment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus.Br. J. Dermatol.159, 1124 1130. doi: 10.1111/j.1365-2133.2008.08804.x Wozniacka, A., Lesiak, A., Narbutt, J., McCauli e, D. P., andSysa-Jedrzejowska, A. (2006). Chloroquine treatment in uences proin ammatory cytokine levels in systemic lupus erythematosus patients.Lupus 15, 268 275. doi: 10.1191/0961203306lu2299oa Wu, Y. W., Tang, W., and Zuo, J. P. (2015). Toll-like receptors: potential targets for lupus treatment.Acta Pharmacol. Sin.36, 1395 1407. doi: 10.1038/aps.2015.91 Wu, Y., He, S., Bai, B., Zhang, L., Xue, L., Lin, Z., et al. (2016).Therapeutic e ects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.Cell. Mol. Immunol. 13, 379 390. doi: 10.1038/cmi.2015.13 Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H.,et al. (2003). Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.Science301, 640 643. doi: 10.1126/science.1087262 Yang, H., Fung, S. Y., and Liu, M. (2011). Programming the cellular uptake of physiologically stable peptide-gold nanoparticle hybrids with singleamino acids. Angew. Chem. Int. Ed. Engl.50, 9643 9646. doi: 10.1002/anie.201 102911 Yang, H., Fung, S. Y., Xu, S., Sutherland, D. P., Kollmann, T. R., Liu, M., et al. (2015). Amino acid-dependent attenuation of toll-like receptor signaling by peptide-gold nanoparticle hybrids.ACS Nano9, 6774 6784. doi: 10.1021/nn505634h Yang, H., Kozicky, L., Saferali, A., Fung, S. Y., Afacan, N., Cai, B., et al. (2016). Endosomal pH modulation by peptide-gold nanoparticle hybrids enables potent anti-in ammatory activity in phagocytic immune cells.Biomaterials 111, 90 102. doi: 10.1016/j.biomaterials.2016.09.032 Yang, H., Zhou, Y. Z., Fung, S. Y., Wu, L. C., Tsai, K., Tan, R. S., et al. (2013). Amino acid structure determines the immune responses generated by peptide-gold nanoparticle hybrids.Part. Part. Syst. Char.30, 1039 1043. doi: 10.1002/ppsc.201300213 Yang, J., Jiang, H., Ding, J. W., Chen, L. H., Li, S., and Zhang, X.D. (2009). Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway.Mol. Cell. Biochem.330, 39 46. doi: 10.1007/s11010-009-0098-1 Yasuda, H., Leelahavanichkul, A., Tsunoda, S., Dear, J. W., Takahashi, Y., Ito, S., et al. (2008). Chloroquine and inhibition of Toll-like receptor 9protect\nFrontiers in Physiology | www.frontiersin.org 19 July 2017 | Volume 8 | Article 508\nfrom sepsis-induced acute kidney injury.Am. J. Physiol. Renal Physiol.294, F1050 F1058. doi: 10.1152/ajprenal.00461.2007\nZhu, F., Jiang, W., Dong, Y., Kandimalla, E., La Monica, N., and Agrawal, S. (2012). IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhib ts disease development in lupus-prone NZBW/F1 mice.J. Immunol.188(1 Suppl.), 119.112. Zhu, F., Yu, D., Kandimalla, E., La Monica, N., and Agrawal, S. (2011). Treatment with IMO-3100, a novel TLR7 and TLR9 dual antagonist, inhibits disease development in lupus prone NZBW/F1 mice, inKeystone Symposia: Dendritic Cells and the Initiation of Adaptive Immunity (Santa Fe, NM). Ziegler, G., Freyer, D., Harhausen, D., Khojasteh, U., Nietfeld, W., and Trendelenburg, G. (2011). Blocking TLR2in vivoprotects against accumulation\nof in ammatory cells and neuronal injury in experimental stroke.J. Cereb. Blood Flow Metab.31, 757 766. doi: 10.1038/jcbfm.2010.161\nCon ict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or nancial relationship that could be construed as a potential con ict of interest.\nCopyright ' 2017 Gao, Xiong, Li and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. Nouse, distribution or reproduction is permitted which does not comply with these terms.\nFrontiers in Physiology | www.frontiersin.org 20 July 2017 | Volume 8 | Article 508"
    } ],
    "references" : [ {
      "title" : "Toll-Like Receptor Antagonists/Inhibitors in Diseases",
      "author" : [ "S. Akira", "K. Takeda" ],
      "venue" : null,
      "citeRegEx" : "Akira and Takeda,? \\Q2004\\E",
      "shortCiteRegEx" : "Akira and Takeda",
      "year" : 2004
    }, {
      "title" : "Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial",
      "author" : [ "F. Arslan", "J.H. Houtgraaf", "B. Keogh", "K. Kazemi", "R. de Jong", "McCormack", "W. J" ],
      "venue" : "B oeng. Transl",
      "citeRegEx" : "Arslan et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Arslan et al\\.",
      "year" : 2012
    }, {
      "title" : "Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 le",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "L.,? \\Q2007\\E",
      "shortCiteRegEx" : "L.",
      "year" : 2007
    }, {
      "title" : "Hydrocortisone reduces the bene cial e e",
      "author" : [ "G.E. chomburg", "B Vollmar" ],
      "venue" : null,
      "citeRegEx" : "chomburg and Vollmar,? \\Q2013\\E",
      "shortCiteRegEx" : "chomburg and Vollmar",
      "year" : 2013
    }, {
      "title" : "Dual role of Toll-like receptors",
      "author" : [ "Kraneveld", "D A" ],
      "venue" : null,
      "citeRegEx" : "J. et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "J. et al\\.",
      "year" : 2012
    }, {
      "title" : "Principles of nanoparticle",
      "author" : [ "H. Shen", "M. Ferrari" ],
      "venue" : null,
      "citeRegEx" : "Blanco et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Blanco et al\\.",
      "year" : 2015
    }, {
      "title" : "Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date.Pharm",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "R.,? \\Q2016\\E",
      "shortCiteRegEx" : "R.",
      "year" : 2016
    }, {
      "title" : "Toll-like receptor 4 inhibition",
      "author" : [ "Dos Santos", "R. A" ],
      "venue" : null,
      "citeRegEx" : "Santos and A,? \\Q2015\\E",
      "shortCiteRegEx" : "Santos and A",
      "year" : 2015
    }, {
      "title" : "Biophysical characterization of the interacti",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "A,? \\Q2002\\E",
      "shortCiteRegEx" : "A",
      "year" : 2002
    }, {
      "title" : "Toll-like receptors 7 and 8 ex",
      "author" : [ "J. ulla", "R Rodriguez-Gonzalez" ],
      "venue" : null,
      "citeRegEx" : "ulla and Rodriguez.Gonzalez,? \\Q2011\\E",
      "shortCiteRegEx" : "ulla and Rodriguez.Gonzalez",
      "year" : 2011
    }, {
      "title" : "Pharmacological inhibition of TLR9 activatio",
      "author" : [ "M Vivarelli" ],
      "venue" : null,
      "citeRegEx" : "S. and Vivarelli,? \\Q2010\\E",
      "shortCiteRegEx" : "S. and Vivarelli",
      "year" : 2010
    }, {
      "title" : "TLR3 is an endogenous sensor of tissue necros",
      "author" : [ "Lukacs", "W N" ],
      "venue" : null,
      "citeRegEx" : "M. et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "M. et al\\.",
      "year" : 2008
    }, {
      "title" : "Toll-like receptors",
      "author" : [ "T. 81370 Celhar", "A.M. Fairhurst" ],
      "venue" : null,
      "citeRegEx" : "Celhar and Fairhurst,? \\Q2014\\E",
      "shortCiteRegEx" : "Celhar and Fairhurst",
      "year" : 2014
    }, {
      "title" : "MicroRNA-155 modulates the interleukin-1 signaling",
      "author" : [ "Santos", "A M" ],
      "venue" : null,
      "citeRegEx" : "W. et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "W. et al\\.",
      "year" : 2009
    }, {
      "title" : "Toll-like receptor 7 and TLR9 dictate autoa",
      "author" : [ "R.A. lavell", "M.J. Shlomchik" ],
      "venue" : null,
      "citeRegEx" : "lavell and Shlomchik,? \\Q2006\\E",
      "shortCiteRegEx" : "lavell and Shlomchik",
      "year" : 2006
    }, {
      "title" : "Lipopolysaccharide induces Alveolar Macrophage Necrosis",
      "author" : [ "W Zhang" ],
      "venue" : null,
      "citeRegEx" : "Zhang,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhang",
      "year" : 2015
    }, {
      "title" : "TLR4/MD-2 monoclonal antibody therapy a ords protect",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "W,? \\Q2007\\E",
      "shortCiteRegEx" : "W",
      "year" : 2007
    }, {
      "title" : "Cutting edge: the nucleotide recept",
      "author" : [ "Dubyak", "G. R" ],
      "venue" : null,
      "citeRegEx" : "Dubyak and R,? \\Q2001\\E",
      "shortCiteRegEx" : "Dubyak and R",
      "year" : 2001
    }, {
      "title" : "The role of toll-like receptors in chronic in ammation",
      "author" : [ "S.K. Drexler", "B.M. Foxwell" ],
      "venue" : "J. Asthma46,",
      "citeRegEx" : "Drexler and Foxwell,? \\Q2010\\E",
      "shortCiteRegEx" : "Drexler and Foxwell",
      "year" : 2010
    }, {
      "title" : "Toll-like receptor 2 expression is decreased on alv",
      "author" : [ "D. Droemann", "T. Goldmann", "T. Tiedje", "P. Zabel", "K. Dalho", "B. Schaaf" ],
      "venue" : null,
      "citeRegEx" : "Droemann et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "Droemann et al\\.",
      "year" : 2005
    }, {
      "title" : "The toll-like receptor",
      "author" : [ "P Knuefermann" ],
      "venue" : null,
      "citeRegEx" : "Knuefermann,? \\Q2011\\E",
      "shortCiteRegEx" : "Knuefermann",
      "year" : 2011
    }, {
      "title" : "ors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles",
      "author" : [ "D. Fang", "S. Yang", "W. Quan", "H. Jia", "Z. Quan", "Z. Qu" ],
      "venue" : "J. Control",
      "citeRegEx" : "Fang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Fang et al\\.",
      "year" : 2014
    }, {
      "title" : "Inhibition of TLR2 promotes graft function in a mu",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "M,? \\Q2012\\E",
      "shortCiteRegEx" : "M",
      "year" : 2012
    }, {
      "title" : "mmatory mediators induced by lipopolysaccharide binding Toll-like receptor 4. Biomaterials100, 6775",
      "author" : [ "G. Foldes", "S. von Haehling", "D.O. Okonko", "E.A. Jankowska" ],
      "venue" : null,
      "citeRegEx" : "Foldes et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Foldes et al\\.",
      "year" : 2016
    }, {
      "title" : "Fluvastatin reduces increased blood",
      "author" : [ "S.D. Anker" ],
      "venue" : null,
      "citeRegEx" : "Anker,? \\Q2008\\E",
      "shortCiteRegEx" : "Anker",
      "year" : 2008
    }, {
      "title" : "Anti-malarial drugs: possible mechanisms of action",
      "author" : [ "R. Fox" ],
      "venue" : null,
      "citeRegEx" : "Fox,? \\Q1996\\E",
      "shortCiteRegEx" : "Fox",
      "year" : 1996
    }, {
      "title" : "Role of Toll-like receptors",
      "author" : [ "M. Fukata", "M.T. Abreu" ],
      "venue" : null,
      "citeRegEx" : "Fukata and Abreu,? \\Q2008\\E",
      "shortCiteRegEx" : "Fukata and Abreu",
      "year" : 2008
    }, {
      "title" : "Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors",
      "author" : [ "S rishnareddy" ],
      "venue" : null,
      "citeRegEx" : "rishnareddy,? \\Q2007\\E",
      "shortCiteRegEx" : "rishnareddy",
      "year" : 2007
    }, {
      "title" : "Psoriasis triggered by toll-like receptor 7 agonist imiquimod",
      "author" : [ "G rg" ],
      "venue" : null,
      "citeRegEx" : "rg,? \\Q2004\\E",
      "shortCiteRegEx" : "rg",
      "year" : 2004
    }, {
      "title" : "Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus",
      "author" : [ "M. Gomez-Guzman", "R. Jimenez", "M. Romero", "M. Sanchez", "M.J. Zarzuelo", "M Gomez-Morales" ],
      "venue" : null,
      "citeRegEx" : "Gomez.Guzman et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Gomez.Guzman et al\\.",
      "year" : 2014
    }, {
      "title" : "TLR recognition of self nucleic acids hampers glucocorticoid activ",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "T,? \\Q2010\\E",
      "shortCiteRegEx" : "T",
      "year" : 2010
    }, {
      "title" : "E ects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles.Biomaterials",
      "author" : [ "C. He", "Y. Hu", "L. Yin", "C. Tang", "C. Yin" ],
      "venue" : null,
      "citeRegEx" : "He et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "He et al\\.",
      "year" : 2010
    }, {
      "title" : "MicroRNAs: new regulators",
      "author" : [ "X. He", "Z. Jing", "G. Cheng" ],
      "venue" : null,
      "citeRegEx" : "He et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "He et al\\.",
      "year" : 2014
    }, {
      "title" : "Toll-like receptor 4 contributes to vascu",
      "author" : [ "A Aguado" ],
      "venue" : null,
      "citeRegEx" : "Aguado,? \\Q2015\\E",
      "shortCiteRegEx" : "Aguado",
      "year" : 2015
    }, {
      "title" : "Role of toll-like receptor 4 in intimal foam cell",
      "author" : [ "J. B", "D. Beasley" ],
      "venue" : null,
      "citeRegEx" : "B. and Beasley,? \\Q2011\\E",
      "shortCiteRegEx" : "B. and Beasley",
      "year" : 2011
    }, {
      "title" : "Helicobacter pylori and gastri",
      "author" : [ "J. Houghton", "T.C. Wang" ],
      "venue" : null,
      "citeRegEx" : "Houghton and Wang,? \\Q2005\\E",
      "shortCiteRegEx" : "Houghton and Wang",
      "year" : 2005
    }, {
      "title" : "In ammation and cancer",
      "author" : [ "X. Yio" ],
      "venue" : null,
      "citeRegEx" : "Itzkowitz and Yio,? \\Q2004\\E",
      "shortCiteRegEx" : "Itzkowitz and Yio",
      "year" : 2004
    }, {
      "title" : "Opposing impact of B cell-intrinsic TLR7 and T",
      "author" : [ "Li", "Q. Z" ],
      "venue" : null,
      "citeRegEx" : "Li and Z,? \\Q2014\\E",
      "shortCiteRegEx" : "Li and Z",
      "year" : 2014
    }, {
      "title" : "IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist",
      "author" : [ "S. grawal" ],
      "venue" : null,
      "citeRegEx" : "grawal,? \\Q2012\\E",
      "shortCiteRegEx" : "grawal",
      "year" : 2012
    }, {
      "title" : "Toll-like receptor-4 mediates cigarette smokeinduced cytokine production by human macrophages",
      "author" : [ "K. Karimi", "H. Sarir", "E. Mortaz", "J.J. Smit", "H. Hosseini", "De Kimpe", "S. J" ],
      "venue" : "J. Immunol.188",
      "citeRegEx" : "Karimi et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Karimi et al\\.",
      "year" : 2006
    }, {
      "title" : "The role of pattern-recognition rec",
      "author" : [ "T. Kawai", "S. Akira" ],
      "venue" : null,
      "citeRegEx" : "Kawai and Akira,? \\Q2010\\E",
      "shortCiteRegEx" : "Kawai and Akira",
      "year" : 2010
    }, {
      "title" : "Toll-like receptor signaling",
      "author" : [ "T. Kawasaki", "T. Kawai" ],
      "venue" : "Nat. Immunol.11,",
      "citeRegEx" : "Kawasaki and Kawai,? \\Q2014\\E",
      "shortCiteRegEx" : "Kawasaki and Kawai",
      "year" : 2014
    }, {
      "title" : "Delayed administration of pituitary",
      "author" : [ "V. Batuman" ],
      "venue" : null,
      "citeRegEx" : "E. and Batuman,? \\Q2012\\E",
      "shortCiteRegEx" : "E. and Batuman",
      "year" : 2012
    }, {
      "title" : "Toll-Like Receptor Antagonists/Inhibitors",
      "author" : [ "W.U. Diseases Kim", "S.A. Yoo", "S.Y. Min", "S.H. Park", "H.S. Koh", "Song", "S. W" ],
      "venue" : null,
      "citeRegEx" : "Kim et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Kim et al\\.",
      "year" : 2006
    }, {
      "title" : "Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus",
      "author" : [ "R asai" ],
      "venue" : null,
      "citeRegEx" : "asai,? \\Q2008\\E",
      "shortCiteRegEx" : "asai",
      "year" : 2008
    }, {
      "title" : "Endosomal TLR signaling is required for anti-nuc",
      "author" : [ "X Du" ],
      "venue" : null,
      "citeRegEx" : "T. and Du,? \\Q2009\\E",
      "shortCiteRegEx" : "T. and Du",
      "year" : 2009
    }, {
      "title" : "Protective role for Toll-like receptor-9 in the development of atheroscle",
      "author" : [ "C ay" ],
      "venue" : null,
      "citeRegEx" : "ay,? \\Q2014\\E",
      "shortCiteRegEx" : "ay",
      "year" : 2014
    }, {
      "title" : "Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines",
      "author" : [ "A. Kuznik", "M. Bencina", "U. Svajger", "M. Jeras", "B. Rozman", "R. Jerala" ],
      "venue" : null,
      "citeRegEx" : "Kuznik et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Kuznik et al\\.",
      "year" : 2011
    }, {
      "title" : "Critical role of TLR2 and TLR4 in autoantibody production",
      "author" : [ "C rnoult" ],
      "venue" : null,
      "citeRegEx" : "rnoult,? \\Q2009\\E",
      "shortCiteRegEx" : "rnoult",
      "year" : 2009
    }, {
      "title" : "TLR7-dependent and FcgammaR-independent production",
      "author" : [ "J st i" ],
      "venue" : null,
      "citeRegEx" : "i,? \\Q2008\\E",
      "shortCiteRegEx" : "i",
      "year" : 2008
    }, {
      "title" : "The role of anti",
      "author" : [ "E. Silverman", "J.M. Bargman" ],
      "venue" : null,
      "citeRegEx" : "Lee et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2011
    }, {
      "title" : "Toll-like receptor 7 preconditioning ind",
      "author" : [ "T. g", "Conrad", "K V" ],
      "venue" : null,
      "citeRegEx" : "g et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "g et al\\.",
      "year" : 2012
    }, {
      "title" : "Ambient ultra ne particles provide a stron",
      "author" : [ "Gookin", "G. R" ],
      "venue" : null,
      "citeRegEx" : "Gookin and R,? \\Q2010\\E",
      "shortCiteRegEx" : "Gookin and R",
      "year" : 2010
    }, {
      "title" : "Phase I and pharmacokinetic studies of C",
      "author" : [ "M Walker" ],
      "venue" : null,
      "citeRegEx" : "Walker,? \\Q2010\\E",
      "shortCiteRegEx" : "Walker",
      "year" : 2010
    }, {
      "title" : "Therapeutic e ects of treatment",
      "author" : [ "Alves-Filho", "J. C" ],
      "venue" : null,
      "citeRegEx" : "Alves.Filho and C,? \\Q2015\\E",
      "shortCiteRegEx" : "Alves.Filho and C",
      "year" : 2015
    }, {
      "title" : "Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems",
      "author" : [ "P.J. Lin", "Y.K. Tam" ],
      "venue" : "PLoS ONE 10:e0132336",
      "citeRegEx" : "Lin and Tam,? \\Q2015\\E",
      "shortCiteRegEx" : "Lin and Tam",
      "year" : 2015
    }, {
      "title" : "TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease",
      "author" : [ "Zhang", "P. L" ],
      "venue" : null,
      "citeRegEx" : "Zhang and L,? \\Q2006\\E",
      "shortCiteRegEx" : "Zhang and L",
      "year" : 2006
    }, {
      "title" : "Pivotal advance: inhibition of MyD88 dimerization and recruitme",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "B,? \\Q2007\\E",
      "shortCiteRegEx" : "B",
      "year" : 2007
    }, {
      "title" : "Increased expression of Toll-like receptors (TLRs) 7 and 9",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "G,? \\Q2014\\E",
      "shortCiteRegEx" : "G",
      "year" : 2014
    }, {
      "title" : "Toll-like receptors and damage-associa",
      "author" : [ "R.C. Webb" ],
      "venue" : null,
      "citeRegEx" : "T. and Webb,? \\Q2014\\E",
      "shortCiteRegEx" : "T. and Webb",
      "year" : 2014
    }, {
      "title" : "Circulating mitochondrial DNA and Toll-like rec",
      "author" : [ "C J" ],
      "venue" : null,
      "citeRegEx" : "J.,? \\Q2015\\E",
      "shortCiteRegEx" : "J.",
      "year" : 2015
    }, {
      "title" : "Antagonistic antibody prevents toll-like recepto",
      "author" : [ "R hwandner" ],
      "venue" : null,
      "citeRegEx" : "hwandner,? \\Q2004\\E",
      "shortCiteRegEx" : "hwandner",
      "year" : 2004
    }, {
      "title" : "Lack of Toll-like receptor 4 or myeloid di erentia",
      "author" : [ "oherty", "T. M" ],
      "venue" : null,
      "citeRegEx" : "oherty and M,? \\Q2004\\E",
      "shortCiteRegEx" : "oherty and M",
      "year" : 2004
    }, {
      "title" : "TGF-alpha regulates TLR expression and function on epidermal keratinocytes",
      "author" : [ "D. ur", "Behmanesh", "B. E" ],
      "venue" : null,
      "citeRegEx" : "ur et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "ur et al\\.",
      "year" : 2005
    }, {
      "title" : "Toll-like receptors and atherosclerosis: oxidiz",
      "author" : [ "Y.I. Miller" ],
      "venue" : null,
      "citeRegEx" : "Miller,? \\Q2005\\E",
      "shortCiteRegEx" : "Miller",
      "year" : 2005
    }, {
      "title" : "Pathogen recognition and in ammatory",
      "author" : [ "T.H. Mogensen" ],
      "venue" : null,
      "citeRegEx" : "Mogensen,? \\Q2009\\E",
      "shortCiteRegEx" : "Mogensen",
      "year" : 2009
    }, {
      "title" : "Toll-like receptor-2 mediates in ammation",
      "author" : [ "M. Feldmann" ],
      "venue" : null,
      "citeRegEx" : "H. and Feldmann,? \\Q2009\\E",
      "shortCiteRegEx" : "H. and Feldmann",
      "year" : 2009
    }, {
      "title" : "NI-0101, a monoclonal antibody targeting toll",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "V,? \\Q2015\\E",
      "shortCiteRegEx" : "V",
      "year" : 2015
    }, {
      "title" : "Toll-like recept",
      "author" : [ "E.M. Moresco", "D. LaVine", "B. Beutler" ],
      "venue" : null,
      "citeRegEx" : "Moresco et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Moresco et al\\.",
      "year" : 2011
    }, {
      "title" : "Cigarette smoke induces CXCL8 production",
      "author" : [ "G. Folkerts" ],
      "venue" : null,
      "citeRegEx" : "Folkerts,? \\Q2010\\E",
      "shortCiteRegEx" : "Folkerts",
      "year" : 2010
    }, {
      "title" : "Inhibition of endotoxin response by e5564, a novel Toll",
      "author" : [ "S yashi" ],
      "venue" : null,
      "citeRegEx" : "yashi,? \\Q2003\\E",
      "shortCiteRegEx" : "yashi",
      "year" : 2003
    }, {
      "title" : "Increased endothelial expression of Toll-like receptor",
      "author" : [ "K. L" ],
      "venue" : null,
      "citeRegEx" : "L.,? \\Q2008\\E",
      "shortCiteRegEx" : "L.",
      "year" : 2008
    }, {
      "title" : "TLR9 regulates TLR7- and MyD88-dependent auto",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "K,? \\Q2010\\E",
      "shortCiteRegEx" : "K",
      "year" : 2010
    }, {
      "title" : "MicroRNA-155 promotes autoimmune in ammation by enhancing in ammatory T cell development",
      "author" : [ "Chaudhuri", "A A" ],
      "venue" : null,
      "citeRegEx" : "L. et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "L. et al\\.",
      "year" : 2010
    }, {
      "title" : "MicroRNA-155 is induced during the macrophage in ammatory response.Proc",
      "author" : [ "R.M. O’Connell", "K.D. Taganov", "M.P. Boldin", "G. Cheng", "D. Baltimore" ],
      "venue" : "Immunity",
      "citeRegEx" : "O.Connell et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "O.Connell et al\\.",
      "year" : 2007
    }, {
      "title" : "Antiin ammatory e ects of reconstituted",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "T,? \\Q1996\\E",
      "shortCiteRegEx" : "T",
      "year" : 1996
    }, {
      "title" : "Pattern recognition recepto",
      "author" : [ "N.W. Palm", "R. Medzhitov" ],
      "venue" : null,
      "citeRegEx" : "Palm and Medzhitov,? \\Q2009\\E",
      "shortCiteRegEx" : "Palm and Medzhitov",
      "year" : 2009
    }, {
      "title" : "rs and control of adaptive immunity",
      "author" : [ "Y. Pan", "T. Jia", "Y. Zhang", "K. Zhang", "R. Zhang", "J Li" ],
      "venue" : "Immunol. Rev",
      "citeRegEx" : "Pan et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Pan et al\\.",
      "year" : 2008
    }, {
      "title" : "Chloroquine for in uenza prevention: a randomise",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "S,? \\Q2011\\E",
      "shortCiteRegEx" : "S",
      "year" : 2011
    }, {
      "title" : "Autoreactive B cell responses to RNArelated antigens due to TLR7 gene duplication",
      "author" : [ "A.B. Satterthwaite", "S. Bolland" ],
      "venue" : null,
      "citeRegEx" : "Satterthwaite and Bolland,? \\Q2006\\E",
      "shortCiteRegEx" : "Satterthwaite and Bolland",
      "year" : 2006
    }, {
      "title" : "A trio of microRNAs",
      "author" : [ "S.R. Quinn", "L.A. O’Neill" ],
      "venue" : null,
      "citeRegEx" : "Quinn and O.Neill,? \\Q2011\\E",
      "shortCiteRegEx" : "Quinn and O.Neill",
      "year" : 2011
    }, {
      "title" : "Randomized, double-blind, placebo-controlled, dose-esca",
      "author" : [ "L hlin" ],
      "venue" : null,
      "citeRegEx" : "hlin,? \\Q2013\\E",
      "shortCiteRegEx" : "hlin",
      "year" : 2013
    }, {
      "title" : "A randomized, double-blind, placebo-controlled tria",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "N,? \\Q2010\\E",
      "shortCiteRegEx" : "N",
      "year" : 2010
    }, {
      "title" : "Bacterial endotoxin: molecular relationships of struc",
      "author" : [ "H Loppnow" ],
      "venue" : null,
      "citeRegEx" : "Loppnow,? \\Q1994\\E",
      "shortCiteRegEx" : "Loppnow",
      "year" : 1994
    }, {
      "title" : "Toll-like receptor 9 plays a key role in the autonomic",
      "author" : [ "Fazan", "R. Jr." ],
      "venue" : null,
      "citeRegEx" : "A. et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "A. et al\\.",
      "year" : 2015
    }, {
      "title" : "Trehalose- and glucose-derived glyco",
      "author" : [ "E.M. ncayo", "A. Oblak", "D Lainscek" ],
      "venue" : null,
      "citeRegEx" : "ncayo et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "ncayo et al\\.",
      "year" : 2014
    }, {
      "title" : "Protection from lethal gram-negative bacterial",
      "author" : [ "A. L", "D Mauri" ],
      "venue" : null,
      "citeRegEx" : "L. and Mauri,? \\Q2009\\E",
      "shortCiteRegEx" : "L. and Mauri",
      "year" : 2009
    }, {
      "title" : "Guanine modi cation of inhibitory oligonucleo",
      "author" : [ "F. Rommler", "M. Jurk", "E. Uhlmann", "M. Hammel", "A. Waldhuber", "L Pfei er" ],
      "venue" : "PLoS ONE 10:e0116703",
      "citeRegEx" : "Rommler et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Rommler et al\\.",
      "year" : 2013
    }, {
      "title" : "Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprot",
      "author" : [ "J e" ],
      "venue" : null,
      "citeRegEx" : "e,? \\Q2004\\E",
      "shortCiteRegEx" : "e",
      "year" : 2004
    }, {
      "title" : "Clinical e cacy and side e ects of antimalarials",
      "author" : [ "M.A. hta" ],
      "venue" : null,
      "citeRegEx" : "hta,? \\Q2010\\E",
      "shortCiteRegEx" : "hta",
      "year" : 2010
    }, {
      "title" : "Toll-like receptor 4 antagonist",
      "author" : [ "J.K. Walker", "D.A. Schwartz" ],
      "venue" : null,
      "citeRegEx" : "Walker and Schwartz,? \\Q2005\\E",
      "shortCiteRegEx" : "Walker and Schwartz",
      "year" : 2005
    }, {
      "title" : "Negative regulation of TLR4 via targ",
      "author" : [ "J.J. O’Leary", "Q Ruan" ],
      "venue" : null,
      "citeRegEx" : "O.Leary and Ruan,? \\Q2010\\E",
      "shortCiteRegEx" : "O.Leary and Ruan",
      "year" : 2010
    }, {
      "title" : "Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury",
      "author" : [ "isig", "A. J" ],
      "venue" : null,
      "citeRegEx" : "isig and J,? \\Q2006\\E",
      "shortCiteRegEx" : "isig and J",
      "year" : 2006
    }, {
      "title" : "Long-term activation of TLR3 by poly",
      "author" : [ "N.C. Stowell", "J. Seideman", "H.A. Raymond", "K.A. Smalley", "Lamb", "R.J. Egenolf", "D. D" ],
      "venue" : null,
      "citeRegEx" : "Stowell et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Stowell et al\\.",
      "year" : 2009
    }, {
      "title" : "Suppression of molecular in ammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin",
      "author" : [ "T. van", "J.G. Krueger" ],
      "venue" : null,
      "citeRegEx" : "van and Krueger,? \\Q2013\\E",
      "shortCiteRegEx" : "van and Krueger",
      "year" : 2013
    }, {
      "title" : "Therapeutic antibod",
      "author" : [ "M. Suzuki", "C. Kato", "A. Kato" ],
      "venue" : null,
      "citeRegEx" : "Suzuki et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Suzuki et al\\.",
      "year" : 2015
    }, {
      "title" : "Toll-like receptors in innate immun",
      "author" : [ "K. Takeda", "S. Akira" ],
      "venue" : null,
      "citeRegEx" : "Takeda and Akira,? \\Q2005\\E",
      "shortCiteRegEx" : "Takeda and Akira",
      "year" : 2005
    }, {
      "title" : "Toll-like receptors",
      "author" : [ "K. Takeda", "T. Kaisho", "S. Akira" ],
      "venue" : "ity. Int",
      "citeRegEx" : "Takeda et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Takeda et al\\.",
      "year" : 2003
    }, {
      "title" : "Modulation of miR-155 and miR-125b levels followin",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "B,? \\Q2007\\E",
      "shortCiteRegEx" : "B",
      "year" : 2007
    }, {
      "title" : "Enhanced immediate in ammatory response",
      "author" : [ "A Igarashi" ],
      "venue" : null,
      "citeRegEx" : "Igarashi,? \\Q2008\\E",
      "shortCiteRegEx" : "Igarashi",
      "year" : 2008
    }, {
      "title" : "Role of Toll-like receptors in the development",
      "author" : [ "H. Mochizuki" ],
      "venue" : null,
      "citeRegEx" : "Mochizuki,? \\Q2008\\E",
      "shortCiteRegEx" : "Mochizuki",
      "year" : 2008
    }, {
      "title" : "Heparin in in ammation: potential therapeutic applications",
      "author" : [ "D.J. Tyrrell", "A.P. Horne", "K.R. Holme", "J.M. Preuss", "C.P. Page" ],
      "venue" : null,
      "citeRegEx" : "Tyrrell et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Tyrrell et al\\.",
      "year" : 1999
    }, {
      "title" : "Toll-like receptors and Type I inter",
      "author" : [ "S. Uematsu", "S. Akira" ],
      "venue" : null,
      "citeRegEx" : "Uematsu and Akira,? \\Q2007\\E",
      "shortCiteRegEx" : "Uematsu and Akira",
      "year" : 2007
    }, {
      "title" : "Blockade of Toll-like receptor 2 prevents spon",
      "author" : [ "J. r nde", "B Keogh" ],
      "venue" : null,
      "citeRegEx" : "nde and Keogh,? \\Q2011\\E",
      "shortCiteRegEx" : "nde and Keogh",
      "year" : 2011
    }, {
      "title" : "Heparin’s anti-in ammatory e ects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins",
      "author" : [ "L. Wang", "J.R. Brown", "A. Varki", "J.D. Esko" ],
      "venue" : null,
      "citeRegEx" : "Wang et al\\.,? \\Q2002\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2002
    }, {
      "title" : "Toll-like receptors",
      "author" : [ "Y.C. Wang", "S. Lin", "Q.W. Yang" ],
      "venue" : null,
      "citeRegEx" : "Wang et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2011
    }, {
      "title" : "Expression of tumour necrosis factor recepto",
      "author" : [ "S.E. Calvano" ],
      "venue" : null,
      "citeRegEx" : "Calvano,? \\Q2005\\E",
      "shortCiteRegEx" : "Calvano",
      "year" : 2005
    }, {
      "title" : "Chloroquine treatment in uences proin ammatory cytokine levels in systemic lupus erythematosus patients",
      "author" : [ "A. Sysa-Jedrzejowska" ],
      "venue" : null,
      "citeRegEx" : "Sysa.Jedrzejowska,? \\Q2006\\E",
      "shortCiteRegEx" : "Sysa.Jedrzejowska",
      "year" : 2006
    }, {
      "title" : "Toll-like receptors: pote",
      "author" : [ "Y.W. Wu", "W. Tang", "J.P. Zuo" ],
      "venue" : "Lupus",
      "citeRegEx" : "Wu et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wu et al\\.",
      "year" : 2015
    }, {
      "title" : "Programming the cellular upta",
      "author" : [ "H. Yang", "S.Y. Fung", "M. Liu" ],
      "venue" : null,
      "citeRegEx" : "Yang et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2011
    }, {
      "title" : "Amino acid-dependent attenuation of toll-like",
      "author" : [ "H. Yang", "S.Y. Fung", "S. Xu", "D.P. Sutherland", "T.R. Kollmann", "M Liu" ],
      "venue" : null,
      "citeRegEx" : "Yang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2015
    }, {
      "title" : "Endosomal pH modulation by peptide-gold nanoparticle hybrids enables potent anti-in ammatory activity in phagocytic immune cells",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "B,? \\Q2016\\E",
      "shortCiteRegEx" : "B",
      "year" : 2016
    }, {
      "title" : "Chloroquine and inhibition of Toll-like receptor",
      "author" : [ ],
      "venue" : null,
      "citeRegEx" : "S,? \\Q2008\\E",
      "shortCiteRegEx" : "S",
      "year" : 2008
    }, {
      "title" : "IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist",
      "author" : [ "S. grawal" ],
      "venue" : null,
      "citeRegEx" : "grawal,? \\Q2012\\E",
      "shortCiteRegEx" : "grawal",
      "year" : 2012
    }, {
      "title" : "Blocking TLR2",
      "author" : [ "G. Trendelenburg" ],
      "venue" : null,
      "citeRegEx" : "Trendelenburg,? \\Q2011\\E",
      "shortCiteRegEx" : "Trendelenburg",
      "year" : 2011
    }, {
      "title" : "hip that could be construed as a potential con ict of interest",
      "author" : [ "Gao", "Xiong", "Li", "Yang" ],
      "venue" : null,
      "citeRegEx" : "Gao et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Gao et al\\.",
      "year" : 2017
    } ],
    "referenceMentions" : [ {
      "referenceID" : 102,
      "context" : "Among all human TLRs, TLR3 exclusively signals through TRIF-dependent pathway while others use MyD88-dependent pathway; ( Uematsu and Akira, 2007) notably, TLR4 can signal through both pathways in a timedependent manner ( Sato et al.",
      "startOffset" : 120,
      "endOffset" : 146
    }, {
      "referenceID" : 64,
      "context" : ", macrophages) and endothelial cells ( Miller, 2005); TLR are also involved in the progression of the disease by lesion orientation ( Edfeldt et al.",
      "startOffset" : 37,
      "endOffset" : 52
    }, {
      "referenceID" : 26,
      "context" : "In particular, chronic gastritis due to Helicobacer pylori infection and severe colitis of patients with in ammatory bowel diseases (IBD) greatly increase the risk of having gastrointestinal malignancies ( Itzkowitz and Yio, 2004; Houghton and Wang, 2005 ), and TLR signaling is evidently involved in such in ammatory complications ( Fukata and Abreu, 2008).",
      "startOffset" : 332,
      "endOffset" : 357
    } ],
    "year" : 0,
    "abstractText" : "The recognition of invading pathogens and endogenous molec ules from damaged tissues by toll-like receptors (TLRs) triggers protectiveself-defense mechanisms. However, excessive TLR activation disrupts the immune home ostasis by sustained pro-in ammatory cytokines and chemokines production and consequently contributes to the development of many in ammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE), infection-associated sepsis, atherosclerosis, and asthma. Therefore, inhibitors/antagonists targeting TLR signals may be bene cial to treat these disorders. In this article, we rst brie y summarize the pat hophysiological role of TLRs in the in ammatory diseases. We then focus on reviewing the cur rent knowledge in both preclinical and clinical studies of various TLR antagonist s/inhibitors for the prevention and treatment of in ammatory diseases. These compounds range from conventional small molecules to therapeutic biologics and nanodevices. In particular, nanodevices are emerging as a new class of potent TLR inhibitors for their unique properties in desired bio-distribution, sustained circulation, and pre ferred pharmacodynamic and pharmacokinetic pro les. More interestingly, the inhibit ory activity of these nanodevices can be regulated through precise nano-functionalization,making them the next generation therapeutics or nano-drugs. Although, signi cant efforts have been made in developing different kinds of new TLR inhibitors/antago nists, only limited numbers of them have undergone clinical trials, and none have been appr oved for clinical uses to date. Nevertheless, these ndings and continuous studies of TLR inhibition highlight the pharmacological regulation of TLR signaling, especially o n multiple TLR pathways, as future promising therapeutic strategy for various in amma tory and autoimmune diseases.",
    "creator" : null
  }
}